



President

Paul A. Greenberger, MD, FAAAAI
Northwestern University Feinberg School of
Medicine
Chicago, IL

President-Elect

Mark Ballow, MD, FAAAAI
Women & Children's Hospital of Buffalo
SUNY Buffalo, School of Medicine & Biomedical
Sciences
Buffalo, NY

Secretary-Treasurer

Dennis K. Ledford, MD, FAAAAI
University of South Florida College of Medicine
James A. Haley V.A. Hospital
Tampa, FL

Immediate Past-President

Hugh A. Sampson, MD, FAAAAI
Mt. Sinai School of Medicine
New York, NY

At-Large Members

Zuhair K. Ballas, MD, FAAAAI
University of Iowa
Iowa City, IA

Bruce S. Bochner, MD, FAAAAI
Johns Hopkins University School of Medicine
Baltimore, MD

A. Wesley Burks, MD, FAAAAI
Duke University Medical Center
Durham, NC

Linda Cox, MD, FAAAAI
Allergy & Asthma Center
Fort Lauderdale, FL

Charlotte Cunningham-Rundles, MD, PhD,
FAAAAAI
Mt. Sinai Medical Center
New York, NY

Mark S. Dykewicz, MD, FAAAAI
Wake Forest University School of Medicine
Winston-Salem, NC

Mary Beth Fasano, MD, FAAAAI
University of Iowa
Iowa City, IA

David P. Huston, MD, FAAAAI
Texas A&M College of Medicine
Houston, TX

Anne-Marie A. Irani, MD, FAAAAI
Virginia Commonwealth University Health
Systems
Richmond, VA

Christopher C. Randolph, MD, FAAAAI
Yale Affiliated Hospitals/Waterbury Hospital
Waterbury, CT

Hugh H. Windom, MD, FAAAAI
Sarasota, FL

Robert A. Wood, MD, FAAAAI
Johns Hopkins University School of Medicine
Baltimore, MD

Executive Vice President

Thomas B. Casale, MD, FAAAAI

Executive Director

Kay Whalen, MBA, CAE

January 28, 2010

Via Electronic Transmission

Senator Charles E. Grassley, Ranking Member
Senate Committee On Finance
219 Dirksen Senate Office Building
Washington, DC 20510-6200

Dear Senator Grassley,

I am writing in response to your December 7, 2009 inquiry.

As you requested, we are attaching a chart outlining all amounts that the AAAAI received from industry (defined as pharmaceutical companies) from 2006 – 2009. This chart does not include the income we have received in exhibit sales and in advertising revenue. Those total amounts are listed below:

2006 130 exhibitors paid a total of \$1,511,900
2007 144 exhibitors paid a total of \$1,672,950
2008 123 exhibitors paid a total of \$1,635,800
2009 111 exhibitors paid a total of \$1,099,800

2006 advertising revenue totaled \$91,405
2007 advertising revenue totaled \$154,750
2008 advertising revenue totaled \$84,125
2009 advertising revenue totaled \$12,400

The attached chart reflects funds received for programs in a given year which is how this is tracked internally. For instance, if funding was received in December of 2005 for the annual meeting in 2006, it is listed on the chart as 2006 funding. Also included on this chart are “pass through” funds. Because of updated ACCME practices, if industry supports an educational event through an unrestricted grant for a regional, state or local allergy society and we provide the CME for these meetings, the funds are sent to the AAAAI. In turn, we forward the funds to the society actually hosting the event.

The responses to your additional five questions follow:

Question 1 – Please describe the policies for accepting industry funding and whether or not AAAAI allows companies to place restrictions or provide guidance on how funding will be spent.

The AAAAI does accept funding from industry to help support our programs. Rather than allowing industry to place restrictions on funding, the AAAAI requests funding

for specific programs and solicits this funding from industry. When accepting funding from industry, we follow the ACCME Guidelines for Commercial Support (attached) as well as the PhRMA Guidelines (attached).

Question 2 – If AAAAI allows companies to place restrictions on industry funding, then please explain all restrictions and/or guidance for each transfer of value from industry. For every transfer of value with a restriction, please provide the following information: year of transfer, name of company, and restriction placed on funding.

When there are restrictions that the AAAAI places on funding, these restrictions are determined through our multi-faceted needs assessment process and our program committee. The attached chart of income received from industry outlines the restrictions placed on the funding that we request from industry. An example of this is the \$1,015,500 grant received from Genentech/Novartis in 2006. These funds were used to develop an on-line practice improvement tool to encourage adherence to NIH NHLBI authored asthma guidelines in an individual physician's practice.

Question 3 – Please explain what policies, if any that AAAAI plans to adopt to ensure transparency of funding in order to provide a greater public trust in the independence of your organization.

The AAAAI has already adopted the ACCME Guidelines for Commercial Support (attached) as well as the PhRMA guidelines (attached). Both of these policies address the transparency issue. In addition, at the beginning of each Board meeting, each individual Board member reviews and updates if necessary his/her disclosure to the full Board.

Question 4 – Please explain your policies on disclosure of outside income by your top executives and board members.

The AAAAI disclosure policy and disclosure review procedure are attached.

Question 5 – Please provide the disclosures of outside income filed with your organization by your top executives and board members.


The COI information attached was provided by individual members in response to standards determined by the AAAAI Ethics Committee and approved by the Board of Directors of the AAAAI. This reported information was subsequently made public. These data reflect activities during the 12 months prior to time that the information was disclosed and not necessarily activities current at the time of the report. The leadership and ethics committee continue to discuss COI concerns for all society activities and the reporting standards have changed over time. In the case of research grants/activities, full time university faculty do not receive any direct compensation from the grants as all funds go directly to their respective institutions and are subject to review by their ethics and COI committees. Not all reported compensation reflects

activities supported/funded by pharmaceutical/medical device companies. Some of the reported income represents compensation for royalties from books, editorships and other independent activities.

We continue to monitor regulations and discussion by the ACCME and PhRMA and other organizations to improve our processes.

Please let me know if you would like additional information.

Sincerely yours,


Paul A. Greenberger, MD, FAAAAI
President



AMERICAN ACADEMY OF ALLERGY
ASTHMA & IMMUNOLOGY

Industry Funds Received 2006

Company	Activity	2006 Received
Alcon Laboratories	Educational Grants	
	Annual Meeting Dinner Symposium	95,000.00
	Sponsorships	
	Annual Meeting Allied Health Reception	7,500.00
	Annual Meeting Allied Health Travel Grants	3,000.00
	Annual Meeting Pop-up Maps	25,000.00
	Subtotal:	130,500.00
Altana Pharma	Educational Grants	
	AAAAI/Clinical Immunology Society Hypersensitivity School	20,000.00
	Allergy, Asthma & Immunology Education and Research Trust	100,000.00
	Allergy Educational Forum	50,000.00
	Annual Meeting Dinner Symposium	95,000.00
	Annual Meeting Dinner Symposium Enduring Material	90,000.00
	Annual Meeting Strategic Training in Allergy Research (ST*AR) Program	75,000.00
	Practicing Allergist (PRACTALL) Meeting on Anaphylaxis	85,000.00
	Sponsorships	
	Annual Meeting Exhibit Hall Pocket Guide	10,000.00
	Annual Meeting Future of the AAAAI Reception	50,000.00
	Annual Meeting Handouts on CD-ROM	40,000.00
	Annual Meeting Hotel Room Key Cards	10,000.00
	Annual Meeting Meeting Planner Guide	35,000.00
	Annual Meeting Posters2View Services	82,200.00
	Annual Meeting Registration Bags	90,000.00
	Subtotal:	832,200.00

AstraZeneca

Educational Grants

Abstract Supplement to Journal of Allergy and Clinical Immunology	135,000.00	
Allergy, Asthma & Immunology Education and Research Trust	10,750.00	
Allergy Educational Forum	50,000.00	
Annual Meeting Allergy and Asthma for the Health Care Professional (AAHCP)		
Program Track	90,000.00	
Annual Meeting Dinner Symposium	95,000.00	
Annual Meeting Dinner Symposium	107,475.50	
William E. Pierson Faculty Visitation Program	32,000.00	

Sponsorships

Annual Meeting Dessert Reception	10,000.00	
Annual Meeting Final Program	60,000.00	

Subtotal: 590,225.50

Aventis Pharmaceuticals

Educational Grants

Allergy & Asthma Disease Management Center (AADMC) Web Site	100,000.00	
Annual Meeting Dinner Symposium	175,315.00	
Clinically Relevant Update on Allergy & Asthma - Jointly Sponsored Program with Eastern Allergy Conference	88,700.00	
Combined Meeting on Allergy, Asthma & Immunology - Jointly Sponsored Program with Southwest Allergy Forum, Eastern Allergy Conference, and the Texas Allergy, Asthma & Immunology Society	124,450.00	
Florida Allergy, Asthma & Immunology Annual Meeting - Jointly Sponsored Program with Florida Allergy, Asthma & Immunology Society	5,000.00	
Program Directors Budget	80,800.00	

Sponsorships

Annual Meeting Preliminary Program	40,000.00	
------------------------------------	-----------	--

Subtotal: 614,265.00

Dey

Educational Grants

Allergy, Asthma & Immunology Education and Research Trust	750.00	
---	--------	--

Sponsorships

Annual Meeting Anaphylaxis Day Activities	30,000.00	
---	-----------	--

Subtotal: 30,750.00

Dynavax Technologies Corp

Educational Grants

Allergy, Asthma & Immunology Education and Research Trust	10,000.00	
---	-----------	--

Subtotal: 10,000.00

Genentech/Novartis

Educational Grants

Allergy, Asthma & Immunology Education and Research Trust	22,500.00	
Annual Meeting Dinner Symposium	180,492.20	
ASTHMA IQ (online practice improvement tool based on NIH NHLBI Guidelines)	1,015,500.00	
Journal of Allergy and Clinical Immunology CME Articles (Current Reviews and Molecular Mechanisms)	120,000.00	

Sponsorships

Annual Meeting Delegate Tracking Cards (Name Badges)	65,000.00	
Annual Meeting Pull and Place Tabs	10,000.00	
Subtotal:		1,413,492.20

GlaxoSmithKline

Educational Grants

2nd Annual Symposium on Allergy, Asthma & Immunology - Jointly Sponsored Program with Ft. Wayne Medical Institute	2,700.00	
AAAAI/American Thoracic Society Pulmonary and Allergy Fellows Program	44,430.35	
Allergy, Asthma & Immunology Education and Research Trust	15,000.00	
Non-Allergic Rhinitis Program (GSK UK)	100,000.00	
Subtotal:		162,130.35

HealthTech Partners

Educational Grants

Allergy, Asthma & Immunology Education and Research Trust	15,000.00	
Subtotal:		15,000.00

Hollister-Stier

Sponsorships

Annual Meeting Fellows-in-Training (FIT) Travel Scholarships	2,000.00	
Subtotal:		2,000.00

Jaffe Family Foundation

Educational Grants

Elliot and Roslyn Jaffe Third-Year Fellowship Food Allergy Research Award at Mount Sinai	66,500.00	
Subtotal:		66,500.00

MedPointe Pharmaceuticals

Educational Grants

Allergy, Asthma & Immunology Education and Research Trust	3,250.00	
Florida Allergy, Asthma & Immunology Annual Meeting - Jointly Sponsored Program with Florida Allergy, Asthma & Immunology Society	5,000.00	

Sponsorships

Annual Meeting Abstracts on CD-ROM	35,000.00	
Annual Meeting Badge Lanyards	15,000.00	
Subtotal:		58,250.00

Merck & Co., Inc.

Educational Grants

2nd Annual Symposium on Allergy, Asthma & Immunology - Jointly Sponsored Program with Ft. Wayne Medical Institute	3,000.00	
10th Annual Symposium on Allergy, Asthma & Immunology - Jointly Sponsored Program with Ft. Wayne Medical Institute	5,000.00	
14th Dees Symposium on Allergy and Immunology - Jointly Sponsored Program with Duke University Medical Center	5,000.00	
AAAAI/Clinical Immunology Society Hypersensitivity School	20,000.00	
Allergy, Asthma & Immunology Education and Research Trust	20,000.00	
Allergy Educational Forum	50,000.00	
Annual Meeting Dinner Symposium	158,590.00	
Annual Meeting Dinner Symposium - Journal of Allergy and Clinical Immunology Supplement	83,900.00	
Annual Meeting New Allergist/Immunologist Assembly Mentorship Program	5,000.00	
Clinically Relevant Update on Allergy & Asthma - Jointly Sponsored Program with Eastern Allergy Conference	7,500.00	
Fall 2006 Symposium on the Los Angeles Society of Allergy, Asthma & Immunology Annual Meeting - Jointly Sponsored Program with Los Angeles Society of Allergy, Asthma & Immunology Society	5,000.00	
Florida Allergy, Asthma & Immunology Annual Meeting - Jointly Sponsored Program with Florida Allergy, Asthma & Immunology Society	5,000.00	
Louisiana Society of Allergy, Asthma & Immunology Annual Meeting - Jointly Sponsored Program with Louisiana Allergy, Asthma & Immunology Society	5,000.00	
Subtotal:		372,990.00

Merck Partnership for Giving

Educational Grants

Allergy, Asthma & Immunology Education and Research Trust	270.00	
Subtotal:		270.00

Pfizer, Inc. & UCB Pharma, Inc.

Educational Grants

Annual Meeting Dinner Symposium	95,000.00
Annual Meeting Dinner Symposium	95,000.00

Sponsorships

Annual Meeting Conference Schedule Board	20,000.00	
Annual Meeting Internet Café	15,000.00	
Subtotal:		225,000.00

Schering-Plough

Educational Grants

AAAAI Strategic Planning Forum	75,000.00	
Annual Meeting Dinner Symposium	95,000.00	
Annual Meeting Pro/Con Debate	20,000.00	
Regional, State and Local Allergy, Asthma and Immunology Governors Strategic Planning Forum	20,000.00	
Regional, State and Local Allergy, Asthma and Immunology Governors Strategic Leadership Forums	175,000.00	

Sponsorships

Annual Meeting Shuttle Bus Service	85,000.00	
Annual Meeting Fellows-in-Training (FIT) Travel Scholarships	110,000.00	
Subtotal:		580,000.00

Sepracor

Educational Grants

Allergy, Asthma & Immunology Education and Research Trust	14,000.00	
AAAAI/Clinical Immunology Society Hypersensitivity School	20,000.00	
Research Excellence Awards	15,000.00	

Sponsorships

Annual Meeting Conference Schedule Board	20,000.00	
Annual Meeting Guest Room Amenities	10,000.00	
Annual Meeting Registration Bag Pens	7,500.00	
Annual Meeting Registration Bag Portfolios	50,000.00	
Annual Meeting President/President-Elect Reception	50,000.00	
Subtotal:		186,500.00

Verus Pharmaceuticals

Educational Grants

Allergy, Asthma & Immunology Education and Research Trust	500.00	
---	--------	--

Sponsorships

Annual Meeting Anaphylaxis Day Activities	30,000.00	
Annual Meeting Internet Café	15,000.00	
Subtotal:		45,500.00

ZLB Behring

Educational Grants

Annual Meeting Dinner Symposium	95,000.00	
Subtotal:		95,000.00

Grand Total: 5,430,573.05



AMERICAN ACADEMY OF ALLERGY
ASTHMA & IMMUNOLOGY

Industry Funds Received 2007

Company	Activity	2007 Received
Alcon Laboratories	Educational Grants	
	Annual Meeting Dinner Symposium	95,000.00
	Sponsorships	
	Annual Meeting Allied Health Reception	7,500.00
	Annual Meeting Allied Health Travel Grants	3,000.00
	Annual Meeting Pop-up Maps	25,000.00
	Subtotal:	130,500.00
Altana Pharma	Educational Grants	
	Annual Meeting Dinner Symposium Online Monograph	90,000.00
	Two Year Allergy/Immunology Research Awards for Advanced Fellows-in-Training	300,000.00
	Sponsorships	
	Annual Meeting Hotel Room Key Cards	10,000.00
	Annual Meeting Registration Bags	90,000.00
	Annual Meeting Exhibit Hall Pocket Guide	10,000.00
	Subtotal:	500,000.00
AstraZeneca	Educational Grants	
	3rd Annual Allergy, Asthma and Immunology Symposium - Jointly Sponsored Program with Ft. Wayne Medical Institute	1,750.00
	Abstract Supplement - Journal of Allergy and Clinical Immunology	140,000.00
	Allergy, Asthma & Immunology Education and Research Trust	27,800.00
	Annual Meeting Allergy and Asthma for the Health Care Professional (AAHCP)	90,000.00
	Annual Meeting Dinner Symposium	95,000.00
	Annual Meeting Workshops (all)	80,000.00
	William E. Pierson Faculty Visitation Program	30,000.00
	Sponsorships	
	Annual Meeting Dessert Reception	10,000.00
	Annual Meeting Final Program	65,000.00
	Annual Meeting Posters2View Services	90,000.00
	Subtotal:	629,550.00

Dey	Sponsorships		
	Anaphylaxis Education Tool Kits Reprint	30,000.00	
		Subtotal:	30,000.00
Genentech/Novartis	Educational Grants		
	Allergy, Asthma & Immunology Education and Research Trust	20,000.00	
	Annual Meeting Dinner Symposium	138,480.00	
	Combined Meeting on Allergy, Asthma and Immunology - Jointly Sponsored Program with Eastern Allergy Conference	73,700.00	
	Florida Allergy, Asthma & Immunology Society 2007 Annual Meeting - Jointly Sponsored Program with Florida Allergy, Asthma & Immunology Society	30,000.00	
	Journal of Allergy and Clinical Immunology CME Articles (Current Reviews and Molecular Mechanisms)	40,000.00	
	Sponsorships		
	Annual Meeting Delegate Tracking Cards (Name Badges)	70,000.00	
	Annual Meeting Pull and Place Tabs in Registration Bags	10,000.00	
		Subtotal:	382,180.00
GlaxoSmithKline	Educational Grants		
	AAAAI/American Thoracic Society Career Development Awards	900,000.00	
	AAAAI/American Thoracic Society Pulmonary and Allergy Fellows Program	59,972.69	
	Annual Meeting Dinner Symposium	95,000.00	
	Annual Meeting Dinner Symposium	95,000.00	
	Annual Meeting Odyssey Program	25,000.00	
	Combined Meeting on Allergy, Asthma & Immunology - Jointly Sponsored Program with Eastern Allergy Conference	10,000.00	
		Subtotal:	1,184,972.69
Hollister-Stier	Sponsorships		
	Annual Meeting Fellows-in-Training (FIT) Travel Grant Scholarships	2,000.00	
		Subtotal:	2,000.00
Jaffe Family Foundation	Educational Grants		
	Elliot and Roslyn Jaffe Third-Year Fellowship Food Allergy Research Award at Mount Sinai	66,500.00	
		Subtotal:	66,500.00
Jerini US	Educational Grants		
	Annual Meeting Dinner Symposium	95,000.00	
		Subtotal:	95,000.00
MedPointe Pharmaceuticals	Sponsorships		
	Annual Meeting Abstracts on CD-ROM	40,000.00	
	Annual Meeting Badge Lanyards	15,000.00	
		Subtotal:	55,000.00

Merck & Co., Inc.

Educational Grants

3rd Annual Allergy, Asthma and Immunology Symposium - Jointly Sponsored Program with Ft. Wayne Medical Institute	4,000.00	
11th Annual Symposium on Allergy, Asthma & Immunology - Jointly Sponsored Program with Fort Wayne Medical Institute	5,000.00	
Anaphylaxis: A Matter of Life and Death - Jointly Sponsored Program with Allergy, Asthma & Immunology Foundation of Northern California	3,500.00	
Allergy Asthma & Immunology Education and Research Trust	10,000.00	
Annual Meeting Breakfast Seminars	90,000.00	
Annual Meeting New Allergist/Immunologist Assembly Mentorship Program	5,000.00	
Fall Symposium of the Los Angeles Society of Allergy, Asthma & Clinical Immunology - Jointly Sponsored Program with the Los Angeles Society of Allergy, Asthma & Clinical Immunology	5,000.00	
Florida Allergy, Asthma & Immunology Society 2007 Annual Meeting - Jointly Sponsored Program with Florida Allergy, Asthma & Immunology Society	7,000.00	
Louisiana Society for Allergy, Asthma & Immunology 34th Annual Meeting - Jointly Sponsored Program with Louisiana Society for Allergy, Asthma & Immunology Society	5,000.00	
University of Washington Allergy and Immunology Journal Club - Jointly Sponsored Program with University of Washington	10,500.00	

Sponsorships

Annual Meeting Fellows-in-Training (FIT) Travel Grant Scholarships	50,000.00	
Subtotal:		195,000.00

Merck Partnership for Giving

Educational Grants

Allergy, Asthma & Immunology Education and Research Trust	210.00	
Subtotal:		210.00

Pfizer, Inc. & UCB Pharma, Inc.

Educational Grants

AAAAI/Clinical Immunology Society Hypersensitivity School	25,000.00	
Annual Meeting Dinner Symposium	95,000.00	

Sponsorships

Annual Meeting Conference Schedule Board	20,000.00	
Annual Meeting Fellows-in-Training (FIT) Travel Grant Scholarships	37,000.00	
Annual Meeting Internet Café	15,000.00	
Subtotal:		192,000.00

Phadia

Educational Grants

Practicing Allergist (PRACTALL) Meeting on Indoor Allergens	10,000.00	
Subtotal:		10,000.00

sanofi-aventis

Educational Grants

11th Annual Symposium on Allergy, Asthma & Immunology - Jointly Sponsored Program with Fort Wayne Medical Institute	3,000.00	
Allergy & Asthma Disease Management Center (AADMC) Web Site	100,000.00	
Annual Meeting Dinner Symposium	95,000.00	
Annual Meeting Dinner Symposium	95,000.00	
Annual Meeting Dinner Symposium Webcast	32,000.00	
Clinically Relevant Updates in Allergy, Asthma & Immunology - Jointly Sponsored Program with Eastern Allergy Conference	147,400.00	
Combined Meeting on Allergy, Asthma & Immunology - Jointly Sponsored Program with Eastern Allergy Conference	147,400.00	
Respiratory Digest CME (Adelphi/MediCine)	90,000.00	

Sponsorships

Annual Meeting Preliminary Program	40,000.00	
Subtotal:		749,800.00

Schering-Plough

Educational Grants

Annual Meeting Dinner Symposium	95,000.00	
Annual Meeting Dinner Symposium Internet-Based Enduring Material	10,000.00	
Regional, State and Local Allergy, Asthma and Immunology Governors Strategic Leadership Forums	175,000.00	
Regional, State and Local Allergy, Asthma and Immunology Governors Strategic Planning Forum	20,000.00	
Underserved Community Fellowship of Excellence Award	100,000.00	

Sponsorships

Annual Meeting Fellows-in-Training (FIT) Travel Grant Scholarships	110,000.00	
Annual Meeting Meeting Planner Guide	35,000.00	
Annual Meeting Shuttle Bus Service	85,000.00	
Subtotal:		630,000.00

Sepracor

Educational Grants

Allergy Educational Forum	50,000.00	
Research Excellence Awards	15,000.00	

Sponsorships

Annual Meeting Conference Schedule Board	20,000.00	
Annual Meeting Guest Room Amenities	10,000.00	
Annual Meeting Registration Bag Pens	7,500.00	
Annual Meeting Registration Bag Portfolios	50,000.00	
Subtotal:		152,500.00

Teva Specialty Pharmaceuticals

Educational Grants

Allergy, Asthma & Immunology Education and Research Trust	112,000.00	
Annual Meeting Allied Health Symposia	15,000.00	
Annual Meeting Military Allergy Program	25,000.00	
Annual Meeting SUNY Stony Brook Alumni Program	3,000.00	
Program Directors Budget	130,000.00	

Sponsorships

Annual Meeting Airport Shuttle Service	10,000.00	
Annual Meeting Fellows-in-Training (FIT) Travel Grant Scholarships	50,000.00	
Annual Meeting Future of the AAAAI Reception	50,000.00	
Subtotal:		395,000.00

Verus Pharmaceuticals

Sponsorships

Annual Meeting Bottled Water	10,000.00	
Annual Meeting Internet Café	15,000.00	
Subtotal:		25,000.00

ZLB Behring

Educational Grants

Annual Meeting Dinner Symposium	95,000.00	
Subtotal:		95,000.00

Grand Total: 5,520,212.69



AMERICAN ACADEMY OF ALLERGY
ASTHMA & IMMUNOLOGY

Industry Funds Received 2008

Company	Activity	2008 Received	
Abbott Laboratories	Educational Grants		
	National Asthma Education and Prevention Program (NAEPP) Asthma Guidelines Supplement Reprint	75,000.00	
		Subtotal:	75,000.00
Abbott Nutrition	Educational Grants		
	2nd International Gastrointestinal Eosinophilic Research Symposium (TIGERS) Meeting in Conjunction with Annual Meeting	10,000.00	
		Subtotal:	10,000.00
Aerocrine	Educational Grants		
	Asthma Specialist Tool to Help Manage Asthma and Improve Quality (ASTHMA IQ) - Web-Based Tool (FENO)	50,000.00	
		Subtotal:	50,000.00
Alcon Laboratories	Sponsorships		
	Annual Meeting Allied Health Reception	7,500.00	
	Annual Meeting Allied Health Travel Scholarships	3,000.00	
	Annual Meeting Handouts on CD-ROM/Printer Kiosks/Online Handouts	50,000.00	
	Annual Meeting Pop-up Maps	27,500.00	
		Subtotal:	88,000.00
American Partnership for Eosinophilic Disorders	Educational Grants		
	2nd International Gastrointestinal Eosinophilic Research Symposium (TIGERS) Meeting in Conjunction with Annual Meeting	5,000.00	
		Subtotal:	5,000.00

AstraZeneca

Educational Grants

4th Annual Symposium on Allergy, Asthma and Immunology - Jointly Sponsored Program with Fort Wayne Medical Institute	3,500.00	
Allergy, Asthma & Immunology Education and Research Trust	30,000.00	
Annual Meeting Dinner Symposium	95,000.00	
Annual Meeting Dinner Symposium Webcast	25,000.00	
William E. Pierson Faculty Visitation Program	32,000.00	

Sponsorships

Annual Meeting Dessert Reception	15,000.00	
Annual Meeting Final Program	70,000.00	

Subtotal: 270,500.00

Children's Digestive Health and Nutrition Foundation

Educational Grants

2nd International Gastrointestinal Eosinophilic Research Symposium (TIGERS) Meeting in Conjunction with Annual Meeting	5,000.00	
--	----------	--

Subtotal: 5,000.00

Ception Therapeutics

Educational Grants

2nd International Gastrointestinal Eosinophilic Research Symposium (TIGERS) Meeting in Conjunction with Annual Meeting	10,000.00	
--	-----------	--

Subtotal: 10,000.00

Children's Hospital of Philadelphia

Educational Grants

2nd International Gastrointestinal Eosinophilic Research Symposium (TIGERS) Meeting in Conjunction with Annual Meeting	2,500.00	
--	----------	--

Subtotal: 2,500.00

Food Allergy Initiative

Educational Grants

Food Allergy Research Awards (2)	130,000.00	
----------------------------------	------------	--

Subtotal: 130,000.00

Genentech/Novartis

Educational Grants

Allergy, Asthma & Immunology Education and Research Trust	10,600.00	
Annual Meeting Dinner Symposium	95,000.00	
Clinically Relevant Updates in Allergy, Asthma and Immunology - Jointly Sponsored Program with Eastern Allergy Conference	77,700.00	
Florida Allergy, Asthma and Immunology Society 2008 Annual Meeting - Jointly Sponsored Program with Florida Allergy, Asthma and Immunology Society	25,000.00	

Sponsorships

Annual Meeting Delegate Tracking Cards (Name Badges)	75,000.00	
Annual Meeting Pull and Place Tabs in Registration Bags	10,000.00	

Subtotal: 293,300.00

GlaxoSmithKline

Educational Grants

2nd International Gastrointestinal Eosinophilic Research Symposium (TIGERS)	10,000.00	
AAAAI/American Thoracic Society Career Development Awards	900,000.00	
Annual Meeting Dinner Symposium	47,500.00	
Annual Meeting Dinner Symposium	47,500.00	
Asthma Management in the Emergency Department Journal Supplement	242,100.00	
Asthma Specialist Tool to Help Manage Asthma and Improve Quality (ASTHMA IQ) - Web-Based Tool for the Primary Care Physician	30,000.00	
University of Washington Allergy and Immunology Journal Club - Jointly Sponsored Program with University of Washington	10,000.00	
Virtual Annual Meeting	75,000.00	
What You Need to Know about Allergies & Asthma - Jointly Sponsored Program with Texas Allergy, Asthma and Immunology Society	10,000.00	
Wisconsin Allergy Society 2008 Annual Meeting - Jointly Sponsored Program with Wisconsin Allergy Society	3,200.00	

Subtotal: 1,375,300.00

HealthTech Partners

Educational Grants

Allergy, Asthma & Immunology Education and Research Trust	10,500.00	
---	-----------	--

Subtotal: 10,500.00

Hollister-Stier

Sponsorships

Annual Meeting Fellows-in-Training (FIT) Travel Grant Scholarships	2,000.00	
--	----------	--

Subtotal: 2,000.00

Jaffe Family Foundation

Educational Grants

Food Allergy Research Award	66,500.00	
-----------------------------	-----------	--

Subtotal: 66,500.00

Jerini US

Educational Grants

Annual Meeting Dinner Symposium	50,000.00	
---------------------------------	-----------	--

Subtotal: 50,000.00

Johnson & Johnson - check came
from medcom

Sponsorships

Annual Meeting Wireless Internet Access	25,000.00	
---	-----------	--

Subtotal: 25,000.00

Lev Pharmaceuticals

Educational Grants

Annual Meeting Dinner Symposium	50,000.00	
---------------------------------	-----------	--

Subtotal: 50,000.00

MedPointe Pharmaceuticals

Educational Grants

Allergy, Asthma & Immunology Education and Research Trust	16,250.00
---	-----------

Sponsorships

Annual Meeting Abstracts on CD-ROM	50,000.00
Annual Meeting Badge Lanyards	15,000.00
Annual Meeting Conference Schedule Board (Convention Center)	25,000.00
Annual Meeting Internet Café (Outside Exhibit Hall)	20,000.00
Annual Meeting Luggage & Coat Check	10,000.00

Subtotal:	136,250.00
------------------	-------------------

Merck & Co., Inc.

Educational Grants

12th Annual Symposium on Allergy, Asthma & Immunology- Jointly Sponsored Program with Fort Wayne Medical Institute	5,000.00
4th Annual Symposium on Allergy, Asthma and Immunology - Jointly Sponsored Program with Fort Wayne Medical Institute	5,000.00
Allergy, Asthma & Immunology Education and Research Trust	10,000.00
Annual Meeting Breakfast Seminars	90,000.00
Annual Meeting New Allergist/Immunologist Assembly Mentorship Program	10,000.00
Bad Genes: New Insights into Disease - Jointly Sponsored Program with Allergy, Asthma and Immunology Foundation of Northern California	2,000.00
Florida Allergy, Asthma & Immunology Society 2008 Annual Meeting - Jointly Sponsored Program with Florida Allergy, Asthma & Immunology Society	7,500.00
Hispanic American Allergy, Asthma and Immunology Association International Update on Allergic Diseases - Jointly Sponsored Program with Hispanic American Allergy, Asthma and Immunology Association	10,000.00
Journal of Allergy and Clinical Immunology (JACI) CME Review Articles (Molecular Mechanisms)	60,000.00
Los Angeles Society of Allergy, Asthma & Immunology 2008 Fall Symposium - Jointly Sponsored Program with Los Angeles Society of Allergy, Asthma & Immunology	5,000.00

Louisiana Society of Allergy, Asthma & Immunology 35th Annual Meeting - Jointly Sponsored Program with Louisiana Society of Allergy, Asthma & Immunology	5,000.00
National Asthma Education and Prevention Program (NAEPP) Asthma Guidelines Supplement Reprint	75,000.00
University of Washington Allergy and Immunology Journal Club - Jointly Sponsored Program with University of Washington	27,000.00
Wisconsin Allergy Society 2008 Annual Meeting - Jointly Sponsored Program with Wisconsin Allergy Society	1,500.00

Sponsorships

Annual Meeting Fellows-in-Training (FIT) Travel Grant Scholarships	75,000.00
--	-----------

Subtotal:	388,000.00
------------------	-------------------

Merck Partnership for Giving	Educational Grants		
	Allergy, Asthma & Immunology Education and Research Trust	300.00	
		Subtotal:	300.00
Phadia	Educational Grants		
	Annual Meeting Dinner Symposium	95,000.00	
		Subtotal:	95,000.00
Pharmaxis, Inc.	Educational Grants		
	Allergy, Asthma & Immunology Education and Research Trust	2,000.00	
		Subtotal:	2,000.00
sanofi-aventis	Educational Grants		
	12th Annual Symposium on Allergy, Asthma & Immunology- Jointly Sponsored Program with Fort Wayne Medical Institute	3,000.00	
	Allergy & Asthma Disease Management Center (AADMC) Web Site	110,000.00	
	Annual Meeting Dinner Symposium	47,500.00	
	Annual Meeting Dinner Symposium	47,500.00	
	Clinically Relevant Updates in Allergy, Asthma and Immunology - Jointly Sponsored Program with Eastern Allergy Conference	33,500.00	
	Combined Meeting on Allergy, Asthma and Immunology - Jointly Sponsored Program with Southwest Allergy Forum, Eastern Allergy Conference, and Texas Allergy, Asthma & Immunology Society	77,700.00	
	Florida Allergy, Asthma & Immunology Society 2008 Annual Meeting - Jointly Sponsored Program with Florida Allergy, Asthma & Immunology Society	8,000.00	
	Hispanic American Allergy, Asthma and Immunology Association International Update on Allergic Diseases - Jointly Sponsored Program with Hispanic American Allergy, Asthma and Immunology Association	15,000.00	
	University of Washington Allergy and Immunology Journal Club - Jointly Sponsored Program with University of Washington	6,000.00	
	Sponsorships		
	Annual Meeting Preliminary Program	50,000.00	
		Subtotal:	398,200.00
Schering-Plough	Educational Grants		
	AAAAI/Clinical Immunology Society Hypersensitivity School	79,741.80	
	Annual Meeting Dinner Symposium	95,000.00	
	Sponsorships		
	Annual Meeting Meeting Planner Guide	40,000.00	
	Annual Meeting Shuttle Bus Service	85,000.00	
		Subtotal:	299,741.80

Sepracor

Educational Grants

Allergy, Asthma & Immunology Education and Research Trust	10,000.00
Annual Meeting Odyssey Program	10,000.00
Research Excellence Awards	15,000.00

Sponsorships

Annual Meeting Conference Schedule Board (Convention Center)	25,000.00
Annual Meeting Guest Room Amenities	15,000.00
Annual Meeting Registration Bag Pens	10,000.00
Annual Meeting Registration Bag Portfolios	50,000.00

Subtotal: 135,000.00

Teva Specialty Pharmaceuticals

Educational Grants

AAAAI/American College of Allergy, Asthma & Immunology Board Review Course with Webinars	250,000.00
Abstract Supplement to Journal of Allergy and Clinical Immunology (JACI)	100,000.00
Allergy, Asthma & Immunology Education and Research Trust	37,000.00
Annual Meeting Advanced Practice Course & Reception (Allied Health)	75,000.00
Annual Meeting Fellows-in-Training (FIT) Program	50,000.00
Annual Meeting Military Allergy Program	25,000.00
Annual Meeting NIH Alumni Event	15,000.00
Annual Meeting SUNY Stony Brook Alumni Event	3,000.00
Program Directors Budget	130,000.00
Respiratory Digest CME Articles - Jointly Sponsored Program with MediCine, Inc.	420,000.00

Sponsorships

Annual Meeting Airport Shuttle Service	15,000.00
Annual Meeting Fellows-in-Training (FIT) Travel Grant Scholarships	50,000.00
Annual Meeting Hotel Room Key Cards	25,000.00
Annual Meeting Registration Bags	100,000.00

Subtotal: 1,295,000.00

Verus Pharmaceuticals

Educational Grants

Allergy, Asthma & Immunology Education and Research Trust	2,000.00
---	----------

Sponsorships

Annual Meeting Bottled Water	10,000.00
Annual Meeting Internet Café (Inside Exhibit Hall)	20,000.00

Subtotal: 32,000.00

Grand Total: 5,300,091.80



AMERICAN ACADEMY OF ALLERGY
ASTHMA & IMMUNOLOGY

Industry Funds Received 2009

Company	Activity		2009 Received
Alcon Laboratories	Sponsorships		
	Annual Meeting Handouts on CD-ROM and Online Handouts	40,000.00	
		Subtotal:	40,000.00
AstraZeneca	Educational Grants		
	Allergy, Asthma & Immunology Education and Research Trust	30,000.00	
	Louisiana Society of Allergy, Asthma and Immunology Annual Meeting - Jointly Sponsored Program with Louisiana Society of Allergy, Asthma and Immunology	2,000.00	
	The Allergist as Consultant - Jointly Sponsored Program with Allergy, Asthma and Immunology Foundation of Northern California	8,000.00	
		Subtotal:	40,000.00
CSL Behring	Educational Grants		
	Allergy, Asthma & Immunology Education and Research Trust	10,000.00	
		Subtotal:	10,000.00
Dey	Sponsorships		
	Anaphylaxis Education Tool Kits Reprint	32,000.00	
		Subtotal:	32,000.00
Dyx Corp.	Educational Grants		
	Annual Meeting Dinner Symposium	31,666.00	
		Subtotal:	31,666.00
Food Allergy Initiative	Educational Grants		
	Food Allergy Research Award	65,000.00	
		Subtotal:	65,000.00
Genentech/Novartis	Educational Grants		
	Allergy, Asthma & Immunology Education and Research Trust	10,000.00	
		Subtotal:	10,000.00

GlaxoSmithKline

Educational Grants

AAAAI/American Thoracic Society Career Development Awards	827,477.00
Annual Meeting Dinner Symposium	47,500.00
Annual Meeting Fellows-in-Training (FIT) Program	25,000.00
Virtual Annual Meeting	45,000.00

Sponsorships

Annual Meeting Fellows-in-Training (FIT) Travel Grant Scholarships	27,500.00
Annual Meeting Non-CME Educational Program	75,000.00

Subtotal: 1,047,477.00

Meda Pharmaceuticals

Sponsorships

Annual Meeting Abstracts on CD-ROM	60,000.00
------------------------------------	-----------

Subtotal: 60,000.00

Merck & Co., Inc.

Educational Grants

5th Annual Symposium on Allergy, Asthma and Immunology - Jointly Sponsored Program with Fort Wayne Medical Institute	5,000.00
Allergy, Asthma & Immunology Education and Research Trust	10,000.00
Annual Meeting Breakfast Seminars	90,000.00
Annual Meeting New Allergist/Immunologist Assembly Mentorship Program	10,000.00
Annual Meeting Underrepresented Allergy/Immunology Networking Program	3,500.00
Florida Allergy, Asthma & Immunology Society 2009 Annual Meeting - Jointly	7,500.00
International Update in Allergic Diseases - Jointly Sponsored Program with Hispanic American Allergy & Immunology Association	10,000.00
Journal of Allergy and Clinical Immunology (JACI) CME Review Articles (Molecular Mechanisms)	60,000.00

Louisiana Society of Allergy, Asthma and Immunology Annual Meeting - Jointly Sponsored Program with Louisiana Society of Allergy, Asthma and Immunology	5,000.00
Los Angeles Society of Allergy, Asthma & Clinical Immunology 2009 Fall Symposium - Jointly Sponsored Program with Los Angeles Society of Allergy, Asthma & Clinical Immunology	5,000.00
The Allergist as Consultant - Jointly Sponsored Program with Allergy, Asthma and Immunology Foundation of Northern California	4,000.00
University of Washington Allergy and Immunology Journal Club - Jointly Sponsored Program with University of Washington	12,500.00
Wisconsin Allergy Society 2009 Annual Meeting - Jointly Sponsored Program with Wisconsin Allergy Society	1,500.00

Sponsorships

Annual Meeting Non-CME Program	75,000.00
Annual Meeting Fellows-in-Training (FIT) Travel Grant Scholarships	75,000.00

Merck Partnership for Giving		Subtotal:	374,000.00
	Educational Grants		
	Allergy, Asthma & Immunology Education and Research Trust	180.00	
		Subtotal:	180.00
Pharmaxis, Inc.			
	Educational Grants		
	Allergy, Asthma & Immunology Education and Research Trust	5,000.00	
		Subtotal:	5,000.00
sanofi-aventis	Educational Grants		
	Allergic Rhinitis, Histamine and Relationship to Other Disease States - Jointly		
	Sponsored Program with Eastern Allergy Conference	79,700.00	
	Annual Meeting Dinner Symposium	95,000.00	
	Florida Allergy, Asthma & Immunology Society 2009 Annual Meeting - Jointly		
	Sponsored Program with Florida Allergy, Asthma & Immunology Society	15,000.00	
	Novel Approaches to Asthma Treatment - Jointly Sponsored Program with		
	Broward Palm Beach Society	5,000.00	
	University of Washington Allergy and Immunology Journal Club - Jointly		
	Sponsored Program with University of Washington	3,500.00	
		Subtotal:	198,200.00
Sciele Pharma			
	Educational Grants		
	Allergy, Asthma & Immunology Education and Research Trust	500.00	
		Subtotal:	500.00
Schering-Plough	Educational Grants		
	5th Annual Symposium on Allergy, Asthma and Immunology - Jointly Sponsored		
	Program with Fort Wayne Medical Institute	1,000.00	
	13th Annual Symposium on Allergy, Asthma and Immunology - Jointly		
	Sponsored Program with Fort Wayne Medical Institute	500.00	
	Sponsorships		
	Annual Meeting Fellows-in-Training (FIT) Travel Grant Scholarships	45,000.00	
	Annual Meeting Final Program	70,000.00	
	Annual Meeting Internet Café	20,000.00	
	Annual Meeting Meeting Planner Guide	40,000.00	
		Subtotal:	176,500.00
Shire			
	Educational Grants		
	Annual Meeting Dinner Symposium	31,666.00	
		Subtotal:	31,666.00

Teva Respiratory

Educational Grants

Allergy, Asthma & Immunology Education and Research Trust	12,000.00
Annual Meeting Military Allergy Program	25,000.00
Annual Meeting NIH Alumni Event	15,000.00
Annual Meeting SUNY Stony Brook Alumni Event	3,000.00

Sponsorships

Annual Meeting Hotel Room Key Cards	25,000.00
Subtotal:	80,000.00

ViroPharma

Educational Grants

Annual Meeting Dinner Symposium	33,666.00
Subtotal:	33,666.00
Grand Total:	2,235,855.00



ACCME STANDARDS FOR COMMERCIAL SUPPORTSM

*Standards to Ensure the
Independence of CME
Activities*

The ACCME Standards for Commercial SupportSM

Standards to Ensure Independence in CME Activities

STANDARD 1: Independence

1.1 A CME provider must ensure that the following decisions were made free of the control of a commercial interest. (See www.accme.org for a definition of a 'commercial interest' and some exemptions.)

- (a) Identification of CME needs;
- (b) Determination of educational objectives;
- (c) Selection and presentation of content;
- (d) Selection of all persons and organizations that will be in a position to control the content of the CME;
- (e) Selection of educational methods;
- (f) Evaluation of the activity.

1.2 A commercial interest cannot take the role of non-accredited partner in a joint sponsorship relationship.¶

STANDARD 2: Resolution of Personal Conflicts of Interest

2.1 The provider must be able to show that everyone who is in a position to control the content of an education activity has disclosed all relevant financial relationships with any commercial interest to the provider. The ACCME defines "relevant" financial relationships" as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

2.2 An individual who refuses to disclose relevant financial relationships will be disqualified from being a planning committee member, a teacher, or an author of CME, and cannot have control of, or responsibility for, the development, management, presentation or evaluation of the CME activity.

2.3 The provider must have implemented a mechanism to identify and resolve all conflicts of interest prior to the education activity being delivered to learners.¶

STANDARD 3: Appropriate Use of Commercial Support

3.1 The provider must make all decisions regarding the disposition and disbursement of commercial support.

3.2 A provider cannot be required by a commercial interest to accept advice or services concerning teachers, authors, or participants or other education matters, including content, from a commercial interest as conditions of contributing funds or services.

3.3 All commercial support associated with a CME activity must be given with the full knowledge and approval of the provider.

Written agreement documenting terms of support

3.4 The terms, conditions, and purposes of the commercial support must be documented in a written agreement between the commercial supporter that includes the provider and its educational partner(s). The agreement must include the provider, even if the support is given directly to the provider's educational partner or a joint sponsor.

3.5 The written agreement must specify the commercial interest that is the source of commercial support.

3.6 Both the commercial supporter and the provider must sign the written agreement between the commercial supporter and the provider.

Expenditures for an individual providing CME

3.7 The provider must have written policies and procedures governing honoraria and reimbursement of out-of-pocket expenses for planners, teachers and authors.

3.8 The provider, the joint sponsor, or designated educational partner must pay directly any teacher or author honoraria or reimbursement of out-of-pocket expenses in compliance with the provider's written policies and procedures.

3.9 No other payment shall be given to the director of the activity, planning committee members, teachers or authors, joint sponsor, or any others involved with the supported activity.

3.10 If teachers or authors are listed on the agenda as facilitating or conducting a presentation or session, but participate in the remainder of an educational event as a learner, their expenses can be reimbursed and honoraria can be paid for their teacher or author role only.

Expenditures for learners

3.11 Social events or meals at CME activities cannot compete with or take precedence over the educational events.

3.12 The provider may not use commercial support to pay for travel, lodging, honoraria, or personal expenses for non-teacher or non-author participants of a CME activity. The provider may use commercial support to pay for travel, lodging, honoraria, or personal expenses for bona fide employees and volunteers of the provider, joint sponsor or educational partner.

Accountability

3.13 The provider must be able to produce accurate documentation detailing the receipt and expenditure of the commercial support. ⌘

STANDARD 4. Appropriate Management of Associated Commercial Promotion

4.1 Arrangements for commercial exhibits or advertisements cannot influence planning or interfere with the presentation, nor can they be a condition of the provision of commercial support for CME activities.

4.2 Product-promotion material or product-specific advertisement of any type is prohibited in or during CME activities. The juxtaposition of editorial and advertising material on the same products or subjects must be avoided. Live (staffed exhibits, presentations) or enduring (printed or electronic advertisements) promotional activities must be kept separate from CME.

- For *print*, advertisements and promotional materials will not be interleaved within the pages of the CME content. Advertisements and promotional materials may face the first or last pages of printed CME content as long as these materials are not related to the CME content they face and are not paid for by the commercial supporters of the CME activity.
- For *computer based*, advertisements and promotional materials will not be visible on the screen at the same time as the CME content and not interleaved between computer 'windows' or screens of the CME content
- For *audio and video recording*, advertisements and promotional materials will not be included within the CME. There will be no 'commercial breaks.'
- For *live, face-to-face CME*, advertisements and promotional materials cannot be displayed or distributed in the educational space immediately before, during, or after a CME activity. Providers cannot allow representatives of Commercial Interests to engage in sales or promotional activities while in the space or place of the CME activity.

4.3 Educational materials that are part of a CME activity, such as slides, abstracts and handouts, cannot contain any advertising, trade name or a product-group message.

4.4 Print or electronic information distributed about the non-CME elements of a CME activity that are not directly related to the transfer of education to the learner, such as schedules and content descriptions, may include product-promotion material or product-specific advertisement.

4.5 A provider cannot use a commercial interest as the agent providing a CME activity to learners, e.g., distribution of self-study CME activities or arranging for electronic access to CME activities. ⌘

STANDARD 5. Content and Format without Commercial Bias

5.1 The content or format of a CME activity or its related materials must promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

5.2 Presentations must give a balanced view of therapeutic options. Use of generic names will contribute to this impartiality. If the CME educational material or content includes trade names, where available trade names from several companies should be used, not just trade names from a single company. ⌘

STANDARD 6. Disclosures Relevant to Potential Commercial Bias

Relevant financial relationships of those with control over CME content

6.1 An individual must disclose to learners any relevant financial relationship(s), to include the following information:

- The name of the individual;
- The name of the commercial interest(s);
- The nature of the relationship the person has with each commercial interest.

6.2 For an individual with no relevant financial relationship(s) the learners must be informed that no relevant financial relationship(s) exist.

Commercial support for the CME activity.

6.3 The source of all support from commercial interests must be disclosed to learners. When commercial support is 'in-kind' the nature of the support must be disclosed to learners.

6.4 'Disclosure' must never include the use of a trade name or a product-group message.

Timing of disclosure

6.5 A provider must disclose the above information to learners prior to the beginning of the educational activity. ⌘



Code on Interactions with Healthcare Professionals

Table of Contents

Preamble	2
1 Basis of Interactions	4
2 Informational Presentations by Pharmaceutical Company Representatives and Accompanying Meals	4
3 Prohibition on Entertainment and Recreation	5
4 Pharmaceutical Company Support For Continuing Medical Education	6
5 Pharmaceutical Company Support for Third-Party Educational or Professional Meetings	7
6 Consultants	7
7 Speaker Programs and Speaker Training Meetings	9
8 Healthcare Professionals Who Are Members of Committees That Set Formularies or Develop Clinical Practice Guidelines	10
9 Scholarships and Educational Funds	11
10 Prohibition of Non-Educational and Practice-Related Items	11
11 Educational Items	12
12 Prescriber Data	13
13 Independence and Decision Making	13
14 Training and Conduct of Company Representatives	14
15 Adherence to Code	14
Questions and Answers	17

Preamble


The Pharmaceutical Research and Manufacturers of America (PhRMA) represents research-based pharmaceutical and biotechnology companies. Our members develop and market new medicines to enable patients to live longer and healthier lives.


Ethical relationships with healthcare professionals are critical to our mission of helping patients by developing and marketing new medicines. An important part of achieving this mission is ensuring that healthcare professionals have the latest, most accurate information available regarding prescription medicines, which play an ever-increasing role in patient healthcare. This document focuses on our interactions with healthcare professionals that relate to the marketing of our products.

Appropriate marketing of medicines ensures that patients have access to the products they need and that the products are used correctly for maximum patient benefit. Our relationships with healthcare professionals are critical to achieving these goals because they enable us to—

- inform healthcare professionals about the benefits and risks of our products to help advance appropriate patient use,
- provide scientific and educational information,
- support medical research and education, and
- obtain feedback and advice about our products through consultation with medical experts.

In interacting with the medical community, we are committed to following the highest ethical standards as well as all legal requirements. We are also concerned that our interactions with healthcare professionals not be perceived as inappropriate by patients or the public at large. This Code is to reinforce our intention that our interactions with healthcare professionals are professional exchanges designed to benefit patients and to enhance the practice of medicine. The Code is based on the principle that a healthcare professional's care of patients should be based, and should be perceived as being based, solely on each patient's medical needs and the healthcare professional's medical knowledge and experience.





Therefore, PhRMA adopts this updated and enhanced voluntary Code on relationships with U.S. healthcare professionals. This Code reflects and builds upon the standards and principles set forth in its predecessor, the PhRMA Code on Interactions with Healthcare Professionals that took effect on July 1, 2002. Like the 2002 edition, this Code addresses interactions with respect to marketed products and related pre-launch activities. PhRMA member companies' relationships with clinical investigators and other individuals and entities as they relate to the clinical research process are addressed in the PhRMA Principles on Conduct of Clinical Trials and Communication of Clinical Trial Results.

This updated Code will take effect in January 2009.

1 Basis of Interactions

Our relationships with healthcare professionals are regulated by multiple entities and are intended to benefit patients and to enhance the practice of medicine. Interactions should be focused on informing healthcare professionals about products, providing scientific and educational information, and supporting medical education.

Promotional materials provided to healthcare professionals by or on behalf of a company should: (a) be accurate and not misleading; (b) make claims about a product only when properly substantiated; (c) reflect the balance between risks and benefits; and (d) be consistent with all other Food and Drug Administration (FDA) requirements governing such communications.

2 Informational Presentations by Pharmaceutical Company Representatives and Accompanying Meals

Informational presentations and discussions by industry representatives and others speaking on behalf of a company provide healthcare providers with valuable scientific and clinical information about medicines that may lead to improved patient care.

In order to provide important scientific information and to respect healthcare professionals' abilities to manage their schedules and provide patient care, company representatives may take the opportunity to present information during healthcare professionals' working day, including mealtimes. In connection with such presentations or discussions, it is appropriate for occasional meals to be offered as a business courtesy to the healthcare professionals as well as members of their staff attending presentations, so long as the presentations provide scientific or educational value and the meals (a) are modest as judged by local standards; (b) are not part of an entertainment or recreational event; and (c) are provided in a manner conducive to informational communication.

Any such meals offered in connection with informational presentations made by field sales representatives or their immediate managers should also be limited to in-office or in-hospital settings.



Inclusion of a healthcare professional's spouse or other guest in a meal accompanying an informational presentation made by or on behalf of a company is not appropriate. Offering "take-out" meals or meals to be eaten without a company representative being present (such as "dine & dash" programs) is not appropriate.

3 Prohibition on Entertainment and Recreation

Company interactions with healthcare professionals are professional in nature and are intended to facilitate the exchange of medical or scientific information that will benefit patient care. To ensure the appropriate focus on education and informational exchange and to avoid the appearance of impropriety, companies should not provide any entertainment or recreational items, such as tickets to the theater or sporting events, sporting equipment, or leisure or vacation trips, to any healthcare professional who is not a salaried employee of the company. Such entertainment or recreational benefits should not be offered, regardless of (1) the value of the items; (2) whether the company engages the healthcare professional as a speaker or consultant, or (3) whether the entertainment or recreation is secondary to an educational purpose.

Modest, occasional meals are permitted as long as they are offered in the appropriate circumstances and venues as described in relevant sections of this Code.

4 Pharmaceutical Company Support for Continuing Medical Education

Continuing medical education (CME), also known as independent medical education (IME), helps physicians and other medical professionals to obtain information and insights that can contribute to the improvement of patient care, and therefore, financial support from companies is appropriate. Such financial support for CME is intended to support education on a full range of treatment options and not to promote a particular medicine. Accordingly, a company should separate its CME grant-making functions from its sales and marketing departments. In addition, a company should develop objective criteria for making CME grant decisions to ensure that the program funded by the company is a bona fide educational program and that the financial support is not an inducement to prescribe or recommend a particular medicine or course of treatment.

Since the giving of any subsidy directly to a healthcare professional by a company may be viewed as an inappropriate cash gift, any financial support should be given to the CME provider, which, in turn, can use the money to reduce the overall CME registration fee for all participants. The company should respect the independent judgment of the CME provider and should follow standards for commercial support established by the Accreditation Council for Continuing Medical Education (ACCME) or other entity that may accredit the CME. When companies underwrite CME, responsibility for and control over the selection of content, faculty, educational methods, materials, and venue belongs to the organizers of the conferences or meetings in accordance with their guidelines. The company should not provide any advice or guidance to the CME provider, even if asked by the provider, regarding the content or faculty for a particular CME program funded by the company.

Financial support should not be offered for the costs of travel, lodging, or other personal expenses of non-faculty healthcare professionals attending CME, either directly to the individuals participating in the event or indirectly to the event's sponsor (except as set out in Section 9 below). Similarly, funding should not be offered to compensate for the time spent by healthcare professionals participating in the CME event.

A company should not provide meals directly at CME events, except that a CME provider at its own discretion may apply the financial support provided by a company for a CME event to provide meals for all participants.



5 Pharmaceutical Company Support for Third-Party Educational or Professional Meetings

Third-party scientific and educational conferences or professional meetings can contribute to the improvement of patient care, and therefore, financial support from companies is appropriate. A conference or meeting is any activity, held at an appropriate location, where (a) the gathering is primarily dedicated, in both time and effort, to promoting objective scientific and educational activities and discourse (one or more educational presentation(s) should be the highlight of the gathering), and (b) the main incentive for bringing attendees together is to further their knowledge on the topic(s) being presented.

Since the giving of any subsidy directly to a healthcare professional by a company may be viewed as an inappropriate cash gift, any financial support should be given to the conference's sponsor, which, in turn, can use the money to reduce the overall conference registration fee for all attendees. When companies underwrite medical conferences or meetings other than their own, responsibility for and control over the selection of content, faculty, educational methods, materials, and venue belongs to the organizers of the conferences or meetings in accordance with their guidelines.

Financial support should not be offered for the costs of travel, lodging, or other personal expenses of non-faculty healthcare professionals attending third-party scientific or educational conferences or professional meetings, either directly to the individuals attending the conference or indirectly to the conference's sponsor (except as set out in Section 9 below). Similarly, funding should not be offered to compensate for the time spent by healthcare professionals attending the conference or meeting.

6 Consultants


Consulting arrangements with healthcare professionals allow companies to obtain information or advice from medical experts on such topics as the marketplace, products, therapeutic areas and the needs of patients. Companies use this advice to inform their efforts to ensure that the medicines they produce and market are meeting the needs of patients. Decisions regarding the selection or retention of healthcare professionals as consultants should be made based on defined criteria such as general medical

expertise and reputation, or knowledge and experience regarding a particular therapeutic area. Companies should continue to ensure that consultant arrangements are neither inducements nor rewards for prescribing or recommending a particular medicine or course of treatment.

It is appropriate for consultants who provide advisory services to be offered reasonable compensation for those services and reimbursement for reasonable travel, lodging, and meal expenses incurred as part of providing those services. Any compensation or reimbursement made in conjunction with a consulting arrangement should be reasonable and based on fair market value.

Token consulting or advisory arrangements should not be used to justify compensating healthcare professionals for their time or their travel, lodging, and other out-of-pocket expenses. The following factors support the existence of a bona fide consulting arrangement (not all factors may be relevant to any particular arrangement):

- a written contract specifies the nature of the consulting services to be provided and the basis for payment of those services;
- a legitimate need for the consulting services has been clearly identified in advance of requesting the services and entering into arrangements with the prospective consultants;
- the criteria for selecting consultants are directly related to the identified purpose and the persons responsible for selecting the consultants have the expertise necessary to evaluate whether the particular healthcare professionals meet those criteria;
- the number of healthcare professionals retained is not greater than the number reasonably necessary to achieve the identified purpose;
- the retaining company maintains records concerning and makes appropriate use of the services provided by consultants;
- the venue and circumstances of any meeting with consultants are conducive to the consulting services and activities related to the services are the primary focus of the meeting; specifically, resorts are not appropriate venues.



While modest meals or receptions may be appropriate during company-sponsored meetings with healthcare professional commercial consultants, companies should not provide recreational or entertainment events in conjunction with these meetings.

It is not appropriate to pay honoraria or travel or lodging expenses to non-faculty and non-consultant healthcare professional attendees at company-sponsored meetings, including attendees who participate in interactive sessions.

7 Speaker Programs and Speaker Training Meetings

Healthcare professionals participate in company-sponsored speaker programs in order to help educate and inform other healthcare professionals about the benefits, risks and appropriate uses of company medicines. Any healthcare professional engaged by a company to participate in such external promotional programs on behalf of the company will be deemed a speaker for purposes of this Code, and the requirements of Section 7 apply to company interactions with that healthcare professional in his or her capacity as a speaker. Company decisions regarding the selection or retention of healthcare professionals as speakers should be made based on defined criteria such as general medical expertise and reputation, knowledge and experience regarding a particular therapeutic area, and communications skills. Companies should continue to ensure that speaking arrangements are neither inducements nor rewards for prescribing a particular medicine or course of treatment.

Speaker training is an essential activity because the FDA holds companies accountable for the presentations of their speakers. It is appropriate for healthcare professionals who participate in programs intended to train speakers for company-sponsored speaker programs to be offered reasonable compensation for their time, considering the value of the type of services provided, and to be offered reimbursement for reasonable travel, lodging, and meal expenses. Such compensation and reimbursement should only be offered when (1) the participants receive extensive training on the company's drug products or other specific topic to be presented and on compliance with FDA regulatory requirements for communications; (2) this training will result in the participants providing a valuable service to the company; and (3) the participants meet the general criteria for bona fide consulting arrangements (as discussed in Section 6 above). Speaker training sessions should

be held in venues that are appropriate and conducive to informational communication and training about medical information; specifically, resorts are not appropriate venues.

Any compensation or reimbursement made to a healthcare professional in conjunction with a speaking arrangement should be reasonable and based on fair market value. Each company should, individually and independently, cap the total amount of annual compensation it will pay to an individual healthcare professional in connection with all speaking arrangements. Each company also should develop policies addressing the appropriate use of speakers, including utilization of speakers after training and the appropriate number of engagements for any particular speaker over time.

Speaker programs may include modest meals offered to attendees and should occur in a venue and manner conducive to informational communication.

While speaker programs offer important educational opportunities to healthcare professionals, they are distinct from CME programs, and companies and speakers should be clear about this distinction. For example, speakers and their materials should clearly identify the company that is sponsoring the presentation, the fact that the speaker is presenting on behalf of the company, and that the speaker is presenting information that is consistent with FDA guidelines. Beyond providing all speakers with appropriate training, companies should periodically monitor speaker programs for compliance with FDA regulatory requirements for communications on behalf of the company about its medicines.

8 Healthcare Professionals Who Are Members of Committees That Set Formularies or Develop Clinical Practice Guidelines

Healthcare professionals who are members of committees that set formularies of covered medicines or develop clinical practice guidelines that may influence the prescribing of medicines often have significant experience in their fields. That experience can be of great benefit to companies and

ultimately to patients if these individuals choose to serve as speakers or commercial consultants for companies. To avoid even the appearance of impropriety, companies should require any healthcare professional who is a member of a committee that sets formularies or develops clinical guidelines and also serves as a speaker or commercial consultant for the company to disclose to the committee the existence and nature of his or her relationship with the company. This disclosure requirement should extend for at least two years beyond the termination of any speaker or consultant arrangement.

Upon disclosure, healthcare professionals who serve as speakers or consultants for companies should be required to follow the procedures set forth by the committee of which they are a member, which may include recusing themselves from decisions relating to the medicine for which they have provided speaking or consulting services.

9 Scholarships and Educational Funds

Financial assistance for scholarships or other educational funds to permit medical students, residents, fellows, and other healthcare professionals in training to attend carefully selected educational conferences may be offered so long as the selection of individuals who will receive the funds is made by the academic or training institution. “Carefully selected educational conferences” are generally defined as the major educational, scientific, or policy-making meetings of national, regional, or specialty medical associations.

10 Prohibition of Non-Educational and Practice-Related Items

Providing items for healthcare professionals’ use that do not advance disease or treatment education — even if they are practice-related items of minimal value (such as pens, note pads, mugs and similar “reminder” items with company or product logos) — may foster misperceptions that company interactions with healthcare professionals are not based on informing them about medical and scientific issues. Such non-educational items should not be offered to healthcare professionals or members of their staff, even if they are accompanied by patient or physician educational materials.

Items intended for the personal benefit of healthcare professionals (such as floral arrangements, artwork, music CDs or tickets to a sporting event) likewise should not be offered.

Payments in cash or cash equivalents (such as gift certificates) should not be offered to healthcare professionals either directly or indirectly, except as compensation for bona fide services (as described in Sections 6 and 7). Cash or equivalent payments of any kind create a potential appearance of impropriety or conflict of interest.

It is appropriate to provide product samples for patient use in accordance with the Prescription Drug Marketing Act.

11 Educational Items

It is appropriate for companies, where permitted by law, to offer items designed primarily for the education of patients or healthcare professionals if the items are not of substantial value (\$100 or less) and do not have value to healthcare professionals outside of his or her professional responsibilities. For example, an anatomical model for use in an examination room is intended for the education of the patients and is therefore appropriate, whereas a DVD or CD player may have independent value to a healthcare professional outside of his or her professional responsibilities, even if it could also be used to provide education to patients, and therefore is not appropriate.

Items designed primarily for the education of patients or healthcare professionals should not be offered on more than an occasional basis, even if each individual item is appropriate.

12 Prescriber Data

Companies use non-patient identified prescriber data to facilitate the efficient flow of information to healthcare professionals. Such prescriber data, which does not identify individual patients, may serve many purposes, including enabling companies to: (a) impart important safety and risk information to prescribers of a particular drug; (b) conduct research; (c) comply with FDA mandated risk management plans that require drug companies to identify and interact with physicians who prescribe certain drugs; (d) track adverse events of marketed prescriptions drugs; and (e) focus marketing activities on those healthcare professionals who would most likely benefit from information about a particular drug.

Companies that choose to use non-patient identified prescriber data to facilitate communications with healthcare professionals should use this data responsibly. For example, companies should (a) respect the confidential nature of prescriber data; (b) develop policies regarding the use of the data; (c) educate employees and agents about those policies; (d) maintain an internal contact person to handle inquiries regarding the use of the data; and (e) identify appropriate disciplinary actions for misuse of this data.

In addition, companies should respect and abide by the wishes of any healthcare professional who asks that his or her prescriber data not be made available to company sales representatives. Companies may demonstrate this respect by following the rules of voluntary programs that facilitate prescribers' ability to make this choice.

13 Independence and Decision Making

No grants, scholarships, subsidies, support, consulting contracts, or educational or practice related items should be provided or offered to a healthcare professional in exchange for prescribing products or for a commitment to continue prescribing products. Nothing should be offered or provided in a manner or on conditions that would interfere with the independence of a healthcare professional's prescribing practices.

14 Training and Conduct of Company Representatives

Pharmaceutical company representatives play an important role in delivering accurate, up-to-date information to healthcare professionals about the approved indications, benefits and risks of pharmaceutical therapies. These representatives often serve as the primary point of contact between the companies who research, develop, manufacture and market life-saving and life-enhancing medicines and the healthcare professionals who prescribe them. As such, the company representatives must act with the highest degree of professionalism and integrity.

Companies should ensure that all representatives who are employed by or acting on behalf of the companies and who visit healthcare professionals receive training about the applicable laws, regulations and industry codes of practice, including this Code, that govern the representatives' interactions with healthcare professionals. In addition, companies should train their representatives to ensure that they have sufficient knowledge of general science and product-specific information to provide accurate, up-to-date information, consistent with FDA requirements.


Companies should provide updated or additional training in all of these areas as needed for their representatives who visit healthcare professionals.

Companies should also assess their representatives periodically to ensure that they comply with relevant company policies and standards of conduct. Companies should take appropriate action when representatives fail to comply.

15 Adherence to Code

All companies that interact with healthcare professionals about pharmaceuticals should adopt procedures to assure adherence to this Code.


Companies that publicly announce their commitment to abide by the Code and who complete an annual certification that they have policies and procedures in place to foster compliance with the Code will be identified by PhRMA on a public web site. The certification must be signed by the company's Chief Executive Officer and Chief Compliance Officer. The web site will identify the companies who commit to abide by the Code; provide



contact information for their Chief Compliance Officers; and, at the appropriate time, publish the status of each company's annual certification.

Any comments received by PhRMA relating to a company's observance of the Code or conduct that is addressed by the Code will be referred by PhRMA to the relevant company's Chief Compliance Officer.

In addition, companies are encouraged to seek external verification periodically, meaning at least once every three years, that the company has policies and procedures in place to foster compliance with the Code. PhRMA will prepare general guidance for such external verification and will identify on its web site if a company has sought and obtained verification of its compliance policies and procedures from an external source.





PRMA
CODE

Questions & Answers

Q.1

Under the Code, may items such as stethoscopes be offered to healthcare professionals?

A. No. Under the Code only items designed primarily for the education of patients or healthcare professionals may occasionally be offered to healthcare professionals, if the items are not of substantial value and do not have a value to healthcare professionals outside of their professional responsibilities. While medical equipment, such as stethoscopes, obviously plays an important role in patient care, such equipment is primarily designed for patient treatment, not for patient or healthcare professional education, and therefore it would be inappropriate for companies to offer such equipment to healthcare professionals.

Q.2

Under the Code, could a company provide healthcare professionals with pens or clipboards designed to be used by healthcare professionals or patients in the healthcare professional's office along with brochures that provide educational information about the company's product?

A. No. The Code states that providing healthcare professionals with items that do not advance disease or treatment education is not appropriate, even if these items are practice-related items of minimal value, such as clipboards, pens, mugs or similar items with or without company logos or product names printed on them. Providing such non-educational items could foster misperceptions that the company's interactions with healthcare professionals are not based on providing information about products or health conditions, and therefore companies should not offer non-educational items to healthcare professionals or their staff, even if they are accompanied by educational materials. It would, however, be appropriate for a company to distribute educational brochures without pens or clipboards. These same guidelines apply with regard to the distribution of items to healthcare professionals at third-party scientific and educational conferences or professional meetings.

Q.3

Under the Code, what are examples of permissible items that may be provided to educate healthcare professionals?

A. The Code states that it is appropriate for companies, where permitted by law, to occasionally offer items primarily designed for the education of patients or healthcare professionals, as long as such items are not of substantial value (\$100 or less) and do not have a value to the healthcare professionals outside of their professional responsibilities. For example, companies may provide educational items such as a medical text book, a subscription to a relevant scientific journal, or copies of relevant clinical treatment guidelines.

Q.4

Under the Code, what types of patient education items may companies provide to healthcare professionals to help them in educating their patients?

A. Where permitted by law, companies may occasionally offer to healthcare professionals items designed to help educate patients, such as anatomical models for examination rooms, informational sheets and brochures, patient self-assessment and tracking tools, or written materials that inform patients about adherence to medicine regimens, healthy lifestyle choices or the availability of patient assistance programs. Such items should not be of substantial value, i.e. they should be \$100 or less.

Companies may also provide to healthcare professionals educational items designed for use by patients to assist in the administration of their treatment or management of their conditions. Such items should only be provided to healthcare professionals for patients where the items are permitted by law, may be considered essential to proper treatment or compliance and where delivery through a healthcare professional is an appropriate method of delivery to the patient. For example, companies may provide through healthcare professionals patient starter kits that help enhance the patients' appropriate use of the prescribed medicine. Providing non-educational items to healthcare professionals for patient use is not appropriate, even if these items are of minimal value, such as pedometers, stopwatches, or other general fitness items.

Q.5

Under the Code, may golf balls and sports bags be provided if they bear a company or product name?

- A.** No. As stated in the prior version of the Code, golf balls and sports bags, even if of minimal value, do not advance disease or treatment education and therefore should not be offered, regardless of whether they bear a company or product name.

Q.6

Under the Code, may healthcare professionals be provided with gasoline for their cars if they are provided with product information at the same time?

- A.** No. As stated in the prior version of the Code, items intended for the personal benefit of a healthcare professional should not be offered.

Q.7

The Code states that company representatives or their immediate managers working in company field sales organizations may conduct informational presentations and discussions accompanied by occasional, modest meals in the healthcare professional's office or hospital setting. What types of presentations and meals would this include?

- A.** An informational presentation or discussion conducted by company representatives or their immediate managers working in field sales may be accompanied by an occasional modest meal in the office or hospital setting. Such modest meals may only be offered provided that the manner of presentation is conducive to a scientific or educational interchange and is not part of an entertainment or recreational event. For example, a sales

representative who is providing scientific or educational information regarding a company's products to one or a few healthcare practitioners working in the same office, could provide a modest meal (e.g., sandwiches or pizza) to physicians and staff attending the representative's informational presentation in the physician's office at lunch time. Providing such modest meals on more than an occasional basis would not be appropriate.

Q.8

Can a field sales representative of Company B conduct an informational presentation accompanied by a meal for a healthcare professional in a restaurant down the street from a hospital?

A. No. An informational presentation or discussion conducted by a field sales representative or her immediate manager may only be accompanied occasionally by a meal if the presentation is held in the healthcare professional's office or hospital. This is to ensure that any meal offered by field sales representatives or their managers is merely incidental to a substantive interaction with a healthcare professional in the office or hospital setting where the healthcare professional typically conducts professional conversations. In addition, any meal offered must be modest as judged by local standards; the presentation must not be part of an entertainment or recreational event; and the presentation must be provided in a manner conducive to informational communication. If a hospital practitioner does not have an office conducive to informational communication, then a presentation may be provided in a hospital cafeteria or other meeting space within the hospital and may be accompanied by a modest meal.

Q.9

A field sales representative of Company X provides pizza for the staff of a medical office during lunch time. Is this consistent with the Code?

- A.** Providing an occasional meal would be consistent with the Code if the sales representative will provide an informational presentation to the medical staff in conjunction with the meal of modest value, so long as the location of the in-office presentation is conducive to scientific or educational communication. Merely dropping off food for the office staff, however, would not be consistent with the Code.

Q.10

A field sales representative of Company X invites physicians to meet to hear a scientific and educational presentation about a new drug at the café at a nearby bookstore. Lunch is provided by the representative and, following the presentation (which is in small groups), each physician is given a gift certificate for books in the amount of \$30. Does this conform to the Code?

- A.** No. While the presentation may present scientific or educational information, a company field sales representative should not provide even a modest meal to healthcare professionals outside of the office or hospital setting (except under the limited circumstances where the field sales representative attends a company-sponsored speaker program to provide logistical support and help monitor compliance with FDA requirements – see Question 13 below). In addition, an open-ended gift certificate is a cash equivalent. A medical textbook, a book on patient care, or a gift certificate redeemable solely for a medical textbook or book on patient care could be provided if it is not of substantial value (\$100 or less).

Q.11

A district sales manager at Company C invites 30 physicians to a corporate suite at a professional baseball game for a 45-minute scientific and educational presentation followed by a buffet and the three-hour game. Does this conform to the Code?

A. No. The provision of entertainment and/or recreational activities, including entertainment at sporting events in connection with an educational or scientific presentation or discussion, is inconsistent with the Code, just as in the prior version. In addition, under the Code, informational presentations by company representatives or their immediate managers in field sales organizations may only be accompanied by a modest meal if the presentations occur in the healthcare professional's office or hospital setting.

Q.12

Under the Code, could a senior business executive employed by a company provide a healthcare professional with an occasional meal outside of the healthcare professional's office or hospital?

A. The Code does not prohibit company employees other than field sales representatives or their immediate managers from providing an occasional meal incidental to a substantive interaction with a healthcare professional outside of his or her office or hospital, as long as (1) the meal is modest as judged by local standards; (2) the meal is not part of an entertainment or recreational event; and (3) the interaction takes place in a venue and manner conducive to informational communication.

Q.13

Company Y would like to engage an expert physician to discuss recent advances in therapy for a group of local health-care professionals, and would like to meet and provide a meal to attendees in the private room of a local restaurant. Under what circumstances can this comply with the Code? Could a local field representative in the company's sales organization attend the event for purposes of assisting the outside speaker and helping to assure that the content of the presentation complies with FDA requirements?

- A.** The Code contemplates that a company may engage a health-care professional to provide medical or scientific information to a group of healthcare professionals on behalf of the company. Such speaker programs may include modest meals offered to attendees and may occur in locations outside of the office or hospital setting, as long as they occur in a venue and manner conducive to informational communication. In this case, Company Y's chosen location of a private room in a local restaurant may be conducive to informational discussion, and the meal provided to attendees should be modest as judged by local standards. In addition, Company Y should follow the provisions of Section 7 of the Code on speaker programs. For example, Company Y should make sure that the speaker is appropriately trained and that the speaker and her materials clearly identify the company sponsoring the presentation and the fact that the speaker is presenting on behalf of the company. In addition, Company Y should periodically monitor its speaker programs for compliance with FDA regulatory requirements. It would be appropriate for a local field representative in the company's sales organization to attend a speaker program for purposes of assisting the speaker with logistics and helping to assure that the content of the presentation complies with FDA requirements.

Q.14

Under what circumstances would the Code permit a company to provide entertainment or recreational activities to healthcare practitioners?

A. Under the Code, companies may not provide entertainment or recreational activities to healthcare practitioners who are not employees of the companies in any context, including situations where those practitioners are providing a legitimate service to the companies, such as when they act as bona fide consultants on an advisory board or are trained at a speaker-training meeting. Thus, companies should not invite healthcare professionals to sporting events, concerts, or shows, or provide them with recreational activities such as hunting, fishing, boating, ski trips, or golf outings, even if those entertainment events or recreational activities are intended to facilitate informational interchanges between the company representative and the healthcare professional. Similarly, it would be inappropriate to provide these types of entertainment and recreational events in conjunction with promotional scientific presentations by medical experts.

Q.15

Company A retains a small group of 15 nationally known physicians regarding a therapeutic area relevant to company A's products to advise on general medical and business issues and provide guidance on product development and research programs for those products. These physicians are paid fees that are typical of the fees paid to thought leaders in this therapeutic area. They normally meet once or twice a year at resort locations to discuss the latest product data, research programs and Company plans. Does this comply with the Code? If it does, is it appropriate to pay for the spouse of the healthcare professional to attend, as well?

A. No, this arrangement for engaging healthcare professionals to obtain advice on the company's commercial operations does not appear to comply with the Code. It is appropriate for companies to engage healthcare professionals to provide bona fide

advisory services as long as the number of healthcare professionals is reasonably necessary to achieve an identified purpose, and they are paid compensation that is reasonable and at fair market value for the services provided. It would not be appropriate, however, to hold such a consultant meeting at a resort venue. In this case, the number of advisors seems reasonably small and the scope of services seems to be reasonably well defined. The advisors seem to have been selected based on their expertise in the areas where advice is needed. The compensation appears consistent with the Code's provision that consultant fees should be reasonable and based on fair market value. Nevertheless, holding consultant meetings at resort locations is not appropriate under the Code. The facilities chosen should be conducive to the services provided as well as reasonable and appropriate to the conduct of the meeting. In addition, only modest meals may be offered to such consultants, and companies should not provide recreational or entertainment events to the healthcare professional consultants in conjunction with these meetings. It would not be appropriate to pay for the cost of the spouse of the advisor. If the spouse attends, it should be at the cost of the advisor.

Q.16

Company A considers whether to invite 300 physicians/consultants to a two-day and one-night speaker-training program at a regional golf resort. All attendees would be compensated for their participation, and their expenses would be reimbursed. Prospective speakers would be selected based on recommendations of the Company's district managers and an assessment of their qualifications by the Company's medical or scientific personnel. Each of the attendees would be required to sign an agreement in advance covering the services they will provide. They would be educated by a faculty on the full range of data surrounding the disease state and the Company's drug product, on presentation skills, and on FDA regulatory requirements. The Company needs to train 300 speakers in order to ensure that enough speakers will actually be available when needed. Training sessions take both days, and the Company provides for a few hours of golf and expensive meals, such as lobster and filet mignon. Does this program conform to the Code? If so, is it appropriate to pay for a spouse of the healthcare professional, as well?

A. No. This arrangement would not conform with the Code. Speaker training is an essential activity because the FDA holds companies accountable for the presentations of their speakers. However, the Code provides that speaker training meetings should be held at appropriate venues and specifically states that resorts are not appropriate venues for training speakers. Moreover, providing entertainment (e.g., golf) and expensive meals to a healthcare professional in a speaker training program would not comply with the Code, although modest meals may be offered to attendees. The Company does appear to satisfy provisions in the Code that require potential speakers to be selected based on defined criteria such as medical expertise, knowledge and experience and to undergo extensive training that would result in a valuable service being provided to the company. The arrangement also appears to meet reasonable indicia of a bona fide consulting relationship. The number of speakers being trained is important; if significantly more participants were trained than the company plans to use as speakers, this arrangement would not comply with the Code. The amount of time spent training speakers should be reasonable in relation to the material that has to be covered. The compensation and lodging offered to prospective speakers should be evaluated to assure that it is reasonable compensation for their time and based on fair market value. It would not be appropriate to pay for the cost of the spouse of the healthcare professional. If the spouse attends, it should be at the cost of the healthcare professional.

Q.17

A sales representative invites a physician out for a round of golf and lunch following the golf. The physician is very busy and is difficult to see in her office. The cost of the golf and the lunch combined are \$65. Does this comply with the Code?

A. No. As stated in the prior version of the Code, it is inconsistent with the Code to provide entertainment or recreational activities such as golf. In addition, occasional, modest meals provided by a representative or his immediate manager working in a field sales organization are limited to in-office or in-hospital settings in conjunction with informational presentations and discussions.



Q.18

Under the Code, may a healthcare professional's spouse or other guest be included in a meal with a pharmaceutical company representative that is provided in connection with an informational presentation by or on behalf of the company, if the healthcare professional pays for the spouse or guest?

A. No. The Code provides that it is not appropriate to include a spouse or guest at a meal in connection with an informational presentation, regardless of who pays for their meal, unless the spouse or guest would independently qualify as a healthcare professional for whom the informational presentation is appropriate.

Q.19

A company is asked to fund a CME program as a “platinum” level supporter. This level of support includes the opportunity for the company to directly sponsor a lunch at the event. May the company become a “platinum” level supporter?

A. It is appropriate under the Code for a company to provide funding to a CME provider, which the provider can use at its discretion to provide meals for all participants. However, a company should not control how the provider spends the funding, and a company should not sponsor or host a meal directly at a CME program. A company may fund a CME program at a particular level of support designated by the CME provider and be publicized for providing that level of support, as long as the company does not separately promote, publicize or otherwise take advantage of any option to be identified as the sponsor of a meal.

Q.20


A national specialty society is holding its three-day annual conference, which includes business meetings, entertainment, and a half day of educational programs for which physicians may receive CME credit. May a company sponsor a reception or lunch at the conference?

A. The Code provides that a company should not provide or sponsor meals directly at CME events. However, at third party conferences or professional meetings at which CME activities comprise only a part of the conference or meeting, a company may sponsor a meal or reception at the conference if it is permitted by the group holding the conference or meeting and is clearly separate from the CME portions of the program. In such cases, any meals or receptions sponsored by a company should be modest and clearly subordinate to the amount of time spent at other aspects of the meeting. In addition, companies should be mindful of standards set forth by ACCME or other accrediting bodies that may apply in these circumstances.

Q.21

May a company publicize its interest in a general topic for a CME program for which a grant would be provided?

A. Yes, a company may communicate to multiple CME providers or the public a general topic for a CME program that might be of interest to physicians. For example, a company may publicize that it will consider funding the topics of new treatments or disease management techniques in a particular therapy area such as diabetes or hypertension. However, the company should follow CME accreditation standards considering the nature and specificity of the CME topics that the company may propose, keeping in mind the Code's statement that financial support for CME is intended to support education on a full range of treatment options and not to promote a particular medicine. In addition, the company may not suggest the speakers or review or make any suggestions concerning the specific content of a particular CME program, even if asked by the CME provider.



Q.22

Under the Code, may a company make a charitable contribution such as purchasing a table at a fundraising dinner or a foursome slot at a fundraising golf tournament?

A. Yes, but the company may not invite healthcare professionals to attend the event at its expense. The company may use some or all of its allotment for its own employees, and return any unused portion to the sponsoring organization to use as it wishes.

Q.23

Under the Code, may a company compensate a consultant for bona fide services by providing an item with a legitimate patient benefit in lieu of paying an honorarium or fee?

A. If the consulting arrangement otherwise complies with the Code, and the fair market value of the item represents reasonable compensation for the services provided, this may be permissible. However, it would be important to comply with all applicable recordkeeping and reporting requirements, just as with cash compensation. The written agreement for the consulting services should set forth the compensation and its fair market value, and disclose that this is taxable income.

Q.24

Does the Code apply to interactions with physician office managers, receptionists, and similar personnel who may not be healthcare professionals?

A. Although the Code does not directly apply to persons who are not healthcare professionals, it would be difficult to separate a company's interactions with any of a physician's employees from those directly with the physician. Therefore, the Code should be followed under these circumstances.

Q.25

Does the Code address the issue of disclosure of company interactions with healthcare professionals who are members of committees that develop formularies or clinical practice guidelines?

A. Yes. The Code states that, to avoid even the appearance of impropriety, companies that have retained a healthcare professional member of a formulary or clinical practice guidelines committee as a commercial consultant or speaker should require the health care professional to disclose to the committee the existence and nature of his or her relationship with the company. This disclosure requirement should extend for at least two years beyond the termination of any consultant or speaker arrangement. Upon disclosure, healthcare professionals should be required to follow the procedures set by the committee of which they are a member; these procedures may include a requirement that healthcare professionals recuse themselves from decisions relating to the medicine about which they provided speaking or consulting services. It is reasonable for a company to rely on healthcare professionals' judgment regarding how to implement these requirements regarding disclosure and subsequent interactions with the committees on which they are members.



Pharmaceutical Research and Manufacturers of America

950 F Street, NW • Washington, DC 20004

www.phrma.org

Revised July 2008



AMERICAN ACADEMY OF ALLERGY
ASTHMA & IMMUNOLOGY

DISCLOSURE POLICY

Reviewed and approved by the Board of Directors, November 4, 2007

Pursuant to the Code of Ethics for the American Academy of Allergy, Asthma and Immunology (AAAAI) and the Standards for Commercial Support of Continuing Medical Education of the Accreditation Council for Continuing Medical Education, the AAAAI requires disclosure of financial and organizational relationships from the following types of individuals:

1. Leaders (officers, Board members, JACI editors, committee chairs/members, and staff);
2. Faculty for scientific meetings and conferences (planning committee members, moderators, and speakers);
3. Participants (at business/committee meetings or other member forums, including involvement in public discourse at scientific meetings and conferences); and
4. Authors of official AAAAI documents.

Disclosure by **Leaders** must be made in writing through use of an official AAAAI Disclosure Form or via the Online Disclosure Management System. A completed form must be returned prior to the commencement of a Leader's term of office. Such disclosure must be updated whenever circumstances require or once per calendar year, whichever is sooner.

Disclosure by **Faculty** must be made in writing through use of an official AAAAI Disclosure Form or via the Online Disclosure Management System. A completed form must be returned prior to the beginning of the Faculty member's involvement in planning or, if a speaker or abstract presenter, before his/her presentation at an AAAAI-sponsored educational activity. Such disclosure must be updated whenever circumstances require or once per calendar year, whichever is sooner. Further, faculty are to disclose to the AAAAI in advance any support they receive or plan to receive in the formulation and development of their presentation. Such support must be approved in advance by the AAAAI.

Faculty who are also speakers must also disclose verbally and visually at the beginning of each presentation. This should be done by the use of a slide or slides, when possible, containing the information on the disclosure form. Speakers are also required to disclose to participants discussion of investigational products or investigational uses of products included in their presentations.

Disclosure by **Participants** must be made verbally at the time a Participant begins speaking at each business/committee meeting or other member forum they attend. Participants are required to disclose their job title and employer, and any other interest of theirs that would be judged by a majority of their peers to be more than casual and/or likely to impact their ability to exercise independent judgment in addressing the issue being discussed.

Disclosure by **Authors** must be made in writing through use of the Disclosure Form or via the Online Disclosure Management System. A completed form must be returned prior to the author beginning work on an AAAAI position statement.

Examples of interests that should be disclosed include, but are not limited to, remuneration received by the individual for any activities performed (such as grants, clinical trials, honoraria, legal or medical consulting fees, etc.), research funding sources, investments, gifts, and organizational affiliations. If the individual's employer fits the definition of a commercial interest*, the individual should describe the scope of his or her work responsibilities (such as administration of specific programs or the topic of research activities). If the individual's employer receives remuneration from a commercial interest for the individual's activities, this relationship should

also be disclosed. Failure to knowingly disclose potential conflicts is a violation of the AAAAI's Code of Ethics and such infringements will be dealt with as detailed in section III.B of the Code of Ethics.

All information disclosed will be reviewed to identify conflicts of interest and to guide the resolution of those conflicts. For Leaders, reviews will be completed by an appropriate AAAAI committee or executive body. For Faculty, reviews will be completed by the Continuing Medical Education Committee or the Annual Meeting Program Committee, depending on the activity in which the faculty member will potentially be involved. For Authors, reviews will be completed by the Practice Diagnostics and Therapeutics Committee.

In all cases, an individual's disclosure will be reviewed in the context of the activity in which s/he will potentially be participating. If a conflict of interest is identified, the reviewers will be asked to identify an appropriate mechanism for resolving the conflict. This could potentially include asking the individual to alter the relationship which creates the conflict, or removing the individual from involvement in the activity. The results of each review will be communicated to the individual and the organization planning the activity to facilitate the resolution of the conflict. The individual will be expected to disclose to the appropriate audience any relationships that were found to be, or to present the potential for, conflicts of interest by the reviewer.

AAAAI members will be expected to update their disclosure information by April 30 of each year, based on the previous calendar year's activities, or when a substantive change in circumstances occurs that would require a revision in the information disclosed.

* A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.



AMERICAN ACADEMY OF ALLERGY
ASTHMA & IMMUNOLOGY

DISCLOSURE FORM

Name: _____

Membership ID Number: _____

Date Completed: _____

A. EMPLOYMENT

My employer is: _____

My job title is: _____

If this employer is defined as a commercial interest (“any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients”), please attach a brief description of job responsibilities:

B. FINANCIAL INTERESTS

I have disclosed below information about all relationships between me or a member of my immediate family or household and any organizations and commercial interests, other than my employer, which may create or be perceived as a conflict of interest. In these relationships one of the following is true:

- the organization or commercial interest has provided remuneration in the previous calendar year (including grants, honoraria, consulting fees, etc.); OR
- I or a member of my immediate family or household invests money in the organization or commercial interest.

Name of Organization	Nature of Relationship	Value < \$10,000	Value ≥ \$10,000

☐ I have no such financial interests to disclose.

C. RESEARCH INTERESTS

I have disclosed below information about all organizations which have supported research projects for which I have served as an investigator or co-investigator during the previous calendar year.

Name of Organization	Nature of Relationship	Value < \$10,000	Value ≥ \$10,000

☐ I have no such research interests to disclose.

D. LEGAL CONSULTATION SERVICES/EXPERT WITNESS TESTIMONY

I have disclosed below information about all topics or issues for which I have provided legal consultation services or expert witness testimony during the previous calendar year. The dollar value of these relationships includes all compensation received related to the topic rather than compensation received on a per case basis.

Topic Consulted or Testified On	Value < \$10,000	Value ≥ \$10,000

E. ORGANIZATIONAL INTERESTS

I have disclosed below information about volunteer positions I have held during the previous calendar year with organizations other than the AAAAI that may create or be perceived as a conflict of interest.

Name of Organization	Nature of Relationship	Value < \$10,000	Value ≥ \$10,000

☐ I have no such organizational interests to disclose.

F. GIFTS

I have disclosed below information about all organizations from which I or a member of my immediate family or household have received a gift during the previous calendar year that may create or be perceived as a conflict of interest.

Name of Organization	Nature of Relationship	Value < \$10,000	Value ≥ \$10,000

☐ I have no such gifts to disclose.

G. OTHER INTERESTS

I have disclosed below any other interest of mine or a member of my immediate family or household that would be judged by a majority of my peers to be more than casual and/or likely to impact my ability to exercise independent judgment. This includes any financial interest in or substantive relationship with any manufacturer of a commercial product, and any financial interest in or relationship with any organization that provides commercial support to AAAAI-sponsored educational activities.

Name of Organization	Nature of Relationship	Value < \$10,000	Value ≥ \$10,000

[] I have no such interests to disclose.

I hereby acknowledge that I occupy a position of trust and that I am expected to act at all times in good faith and in accordance with the Code of Ethics of the AAAAI; and to act in such a manner as to avoid even the appearance of using my position to advance, in a way inconsistent with the purposes and interests of the AAAAI, any private interest of mine or of any individual or entity with whom I have a significant relationship.

I certify that the statements I have made above are true, complete, and correct to the best of my knowledge and belief, and agree to report to the AAAAI any interests or relationships which may subsequently develop or dissolve that would alter these statements in any substantive way.

Signature: _____

Date: _____



AMERICAN ACADEMY OF ALLERGY
ASTHMA & IMMUNOLOGY

Disclosure Review Procedure

revised August 21, 2008

Pursuant to the Code of Ethics for the American Academy of Allergy, Asthma and Immunology (AAAAI) and the Standards for Commercial Support of Continuing Medical Education of the Accreditation Council for Continuing Medical Education, the AAAAI requires disclosure of financial and organizational relationships from the following types of individuals:

1. Leaders (officers, Board members, JACI editors, committee chairs/members, and staff)
 - a. Officers/Board Members
 - Disclosure statements will be reviewed by the CME Committee (*approved on December 12, 2007 ECCC*)
 - Disclosure statements from nominees to the Board of Directors will be reviewed by the Chair of the Nominating Committee prior to the slate of candidates being presented to the Board for ratification
 - b. JACI Editors
 - Disclosure statements will be reviewed by the Ethics Committee
 - c. Committee Chairs/Members
 - Disclosure statements from the majority of Committee Chairs will be reviewed by a committee of all Interest Section Secretaries. Exceptions are listed below. If any conflicts are identified, the disclosure in question will be sent to the Ethics Committee for further review and resolution. (*approved on December 12, 2007 ECCC*)
 - Disclosure statements from Interest Section Chairs, Vice Chairs, and Secretaries will be reviewed by the Ethics Committee (*approved on November 20, 2007 ECCC*)
 - Disclosure statements from the Continuing Medical Education (CME) Committee Chair and members will be reviewed by the Ethics Committee (*approved on December 12, 2007 ECCC*)
 - Disclosure statements from the Ethics Committee Chair and members will be reviewed by the Board of Directors (*approved on December 12, 2007 ECCC*)
 - Disclosure statements from the Needs Assessment Committee Chair and members will be reviewed by the Ethics Committee
 - Disclosure statements from the Practice, Diagnostics & Therapeutics (PDT) Committee Chair and members will be reviewed by the Practice & Policy Division
 - Disclosure statements from the Annual Meeting Program Committee (AMPC) will be reviewed as follows:
 - AMPC Chairs will be reviewed by the Ethics Committee;
 - AMPC Executive Council will be reviewed by the AMPC Chairs;
 - AMPC Subcommittee Chairs will be reviewed by the AMPC Chairs;
 - AMPC Subcommittee members will be reviewed by the leadership of the Interest Section appointing them to the Subcommittee;
 - Allied Health AMPC leadership will be reviewed by the Past Co-Chairs of the Allied Health Assembly;

- Allied Health AMPC Subcommittee members will be reviewed by the Allied Health AMPC Subcommittee Chairs;
 - NAIA AMPC Chairs and members will be reviewed by the NAIA leadership
- 2. Faculty for scientific meetings and conferences (planning committee members, moderators, and speakers)
 - Disclosure statements will be reviewed by either the CME Committee or the Annual Meeting Program Committee (AMPC) depending on the activity
- 3. Participants (at business/committee meetings or other member forums, including involvement in public discourse at scientific meetings and conferences);
 - Disclosure is made verbally at the time of the activity
- 4. Authors of official AAAAI documents
 - Disclosure statements will be reviewed by the PDT Committee



AMERICAN ACADEMY OF ALLERGY
ASTHMA & IMMUNOLOGY

Board of Directors Disclosures
2006-2009

2006

Officers

PLATTS-MILLS, THOMAS - President

Financial	Pharmacia: Research Grant, Sharper Image: Consultant/Educational Grant
Research	CENTERS FOR DISEASE CONTROL: Grants, National Institutes of Health: Grants, Sharper Image: Educational Grant

CASALE, THOMAS – President-Elect

Financial	Adelphi, Inc.: Editorial Board/Author, Adelphi: Editorial Contributions, Outcomes Management Educational Workshops, Inc.: Faculty, Phase V Communications: Consulting, Roche Pharmaceuticals: Data Safety Monitoring Board
Research	Astra Zeneca Pharmaceuticals: Principal Investigator, AstraZeneca: Investigator, Aventis: Consultant, Biogen: Consultant; Investigator, Biogen: Principal Investigator, Bristol Myers Squibb: Consultant, Corixa Pharmaceuticals: Principal Investigator, Dynavax, Pharmaceuticals: Principal Investigator, Forest Laboratories: Consultant, Forest Labs: Consultant, Genentech: Consultant, Health Futures Foundation/Creighton University: Principal Investigator, Idec Pharmaceuticals: Principal Investigator, IDEC: Consultant, Immune Tolerance Network/NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES: Principal Investigator, Merck Pharmaceuticals, Inc.: Principal Investigator, Merck: Consultant, NATIONAL INSTITUTES OF HEALTH: Co-Principal Investigator, Novartis/Genentech: Principal Investigator, Novartis: Consultant Ono, Pharmaceuticals: Principal Investigator, Pfizer: Investigator, Sepracor: Consultant

SIMONS, F. ESTELLE R. – Immediate Past-President

Financial	Nothing to Disclose
Research	Merck : Medical School Grant, UCB Pharma: Grant to Health Sciences Centre/University of Manitoba for investigator-initiated study

GREENBERGER, PAUL – Secretary-Treasurer

Financial	Nothing to Disclose
Research	National Heart, Lung, and Blood Institute: research support

SCHATZ, MICHAEL – Past Past-President

Financial	Astra Zeneca: Speakers Bureau, Merck: Speakers Bureau
Research	Aventis: Grant Support (Asthma burden study using administrative data), Glaxo Smith Kline: Grant Support (Asthma Control Test), GlaxoSmithKline: Research (rhinitis burden)

At-Large Members

BOCHNER, BRUCE

Financial GlaxoSmithKline, Pfizer, Genentech, Novartis, Amgen, sanofi-aventis, Cordis: Consulting, Glycomimetics, Inc., Arriva: Consulting and Scientific Advisory Board, Merck, Genentech, Novartis, sanofi-aventis: Speaker's Bureau, UCB Pharma, Domantis, MedImmune: Consulting

Research GLAXOSMITHKLINE, Eli Lilly, Human Genome Sciences: unfunded scientific collaborations, NATIONAL INSTITUTES OF HEALTH: RO1 and other research grants

BROIDE, DAVID

Financial Nothing to Disclose

Research NATIONAL INSTITUTES OF HEALTH: Research Grants, University of California Tobacco Related Disease Research Program: Research Grants

FLEISHER, THOMAS

Financial Nothing to Disclose

Research Nothing to Disclose

GAWCHIK, SANDRA

Financial Nothing to Disclose

Research Astra Zeneca: Research, GlaxoSmithKline: Research, Novartis: Research, Schering: Research, Sepracor: Research

GOLDSTEIN, STANLEY

Financial Nothing to Disclose

Research Nothing to Disclose

GRUCHALLA, REBECCA

Financial Nothing to Disclose

Research ExxonMobil: A total of \$500,000 was given to Dr. Gruchalla and her research team to conduct a community-based participatory project entitled, "Community Leadership in Preventing Asthma - CLIP Asthma". This study is seeking to evaluate the relationship between allergens in the school and home environments and asthma symptoms in inner city children. The funds are to be spent over a 3 year period. We are in year 02. Dr. Gruchalla is PI.

LEDFORD, DENNIS

Financial Boehringer Ingelheim: Speaker bureau with honoraria, Genentech: Speaker bureau honoraria., GlaxoSKF: Research grant to study effect of long acting beta agonist and fluticasone on animal model of asthma , with viral disease., MedPointe: Consultant and speaker bureau, Merck: Speaker bureau honoraria, Novartis: Consultant and speaker honoraria

Research Genentech: Clinical trial, GlaxoSKF: Clinical trial, MedPointe: Clinical trial, Novartis: Clinical trial, Sanofi Aventis: Clinical COPD trial

LEUNG, DONALD

Financial Nothing to Disclose

Research Glaxo/SKB: Grant

LEVINSON, ARNOLD

Financial	Nothing to Disclose
Research	NATIONAL INSTITUTES OF HEALTH: PI on RO-1, Veterans Administration : PI on Merit Review grant

LI, JAMES

Financial	Astra Zeneca: Research, GLAXOSMITHKLINE: Research
Research	AstraZeneca: Research, GLAXOSMITHKLINE: Research

RANDOLPH, CHRISTOPHER

Financial	AstraZeneca: Speaker's Bureau; Grant Support; Consulting, Aventis: Speaker's Bureau; Grant Support; Consulting, Forest: Speaker's Bureau; Grant Support; Consulting, Glaxo: Speaker's Bureau; Grant Support; Consulting, IVAX: Speaker's Bureau; Grant Support; Consulting, Merck: Speaker's Bureau; Grant Support; Consulting, Novartis: Speaker's Bureau; Grant Support; Consulting, Schering: Speaker's Bureau; Grant Support; Consulting, Sepracor: Speaker's Bureau; Grant Support; Consulting
Research	Nothing to Disclose

Executive Staff**WHALEN, KAY – Executive Vice President**

Financial	Executive Director, Inc.: Ownership Interest
Research	Nothing to Disclose

Officers

CASALE, THOMAS B., MD FAAAAI - President

Financial	Advanced Health Media, Inc: Honoraria; Allux Medical, Inc.: Consulting Fees; American College of Allergy, Asthma & Immunology: Honoraria; Educational Concepts in Medicine: Honoraria; Medesta Associates Inc.: Honoraria; Novartis Pharmaceuticals: Honoraria/Consulting Fees; Gray Consulting, Inc.: Consulting Fees; On Pointe Medical Communications: Honoraria; Sanofi-Aventis: Member DSMB; Washington University: Honoraria; Genentech: Consulting Fees/Honoraria; Dynavax Technologies: Consulting Fees; Gerson Lehrman Group: Consulting Fees; Capnia, Inc.: Consulting Fees; Adelphi: Honoraria
Research	Astellas Pharma, Inc.: Principal Investigator; Schering-Plough: Principal Investigator; Capnia, Inc.: Principal Investigator; Novartis Pharmaceuticals: Principal Investigator; NATIONAL INSTITUTES OF HEALTH: Principal Investigator; Medicinova, Inc.: Principal Investigator; Health Futures Foundation: Principal Investigator; Pharmaxis: Principal Investigator; Dynavax, Inc.: Principal Investigator; Genentech: Principal Investigator; Pfizer, Inc.: Principal Investigator

SAMPSON, HUGH A., MD FAAAAI – President-Elect

Financial	Food Allergy Initiative: Consultant; Allertein Therapeutics, LLC: Consultant on the development of novel vaccines for the treatment of allergic disorders, especially food allergy.
Research	National Institutes of Health; Food Allergy Initiative; and Phadia AB: The following grants are received from the NATIONAL INSTITUTES OF HEALTH: NATIONAL INSTITUTES OF HEALTH PO1 AI44236 “Immunologic Basis of Cow Milk-induced Hypersensitivity.” N01-AI-25496 “Inner-city Asthma Consortium” U19 AI066738 “Immunobiology of Peanut Allergy and its Treatment: a Prototype”

PLATT'S-MILLS, THOMAS A. E., MD PHD FAAAAI – Immediate Past-President

Financial	Sharper Image: Consultant/Educational Grant; Pharmacia: Research Grant
Research	Sharper Image: Educational Grant; National Institutes of Health: Grants; CENTERS FOR DISEASE CONTROL: Grants

GREENBERGER, PAUL MD FAAAAI – Vice President

Financial	Nothing to Disclose
Research	National Heart, Lung, and Blood Institute: research support

BALLOW, MARK, MD FAAAAI – Secretary-Treasurer

Financial	University Pediatric Associates: Practice Plan Patient Care
Research	PBL: Clinical Study on IVIG; NATIONAL INSTITUTES OF HEALTH: Research

SIMONS, F. ESTELLE R., MD FAAAAI – Past Past-President

Financial	Nothing to Disclose
Research	Merck : Medical School Grant; ucb Pharma: Grant to Health Sciences Centre/University of Manitoba for investigator-initiated study

At-Large Members

BALLAS, ZUHAIR K., MD FAAAAI

Financial Baxter, Roche - Consultant; Novartis – member of DSMB;
Research Veterans' Administration – Merit grant recipient; NATIONAL INSTITUTES OF
HEALTH – grant

BOCHNER, BRUCE S., MD FAAAAI

Financial GlaxoSmithKline, Pfizer, Genentech, Novartis, Amgen, sanofi-aventis, Cordis:
Consulting; Glycomimetics, Inc., Arriva: Consulting and Scientific Advisory Board; Merck,
Genentech, Novartis, sanofi-aventis: Speaker's Bureau; UCB Pharma, Domantis,
MedImmune: Consulting
Research NATIONAL INSTITUTES OF HEALTH: RO1 and other research grants;
GLAXOSMITHKLINE, Eli Lilly, Human Genome Sciences: unfunded scientific
collaborations

BROIDE, DAVID H., MB CHB FAAAAI

Financial Nothing to Disclose
Research NATIONAL INSTITUTES OF HEALTH: Research Grants; University of California
Tobacco Related Disease Research Program: Research Grants

BURKS, A. WESLEY, MD FAAAAI

Financial EpiPen/Dey, L.P.: Speaker's Bureau; Dannon Co. Probiotics: Advisory Board; McNeil
Nutritionals: Consultant; Allertein: Minority stockholder; Novartis: Consultant; SHS
International: Expert Panel
Research Gerber: Grantee (PI); National Institutes of Health: Grantee (PI); Food Allergy and
Anaphylaxis Network: Grantee (PI); The Peanut Foundation: Grantee (PI)

COX, LINDA, MD FAAAAI

Financial IVAX, Greer, GLAXOSMITHKLINE, Pfizer, Genentech/Novartis: speaker bureau:
GLAXOSMITHKLINE, IVAX, Genentech/Novartis advisory boards: Greer SLIT,
Genentech/Novartis
Research AAAAI: provided grant for extract stability study

CUNNINGHAM-RUNDLES, CHARLOTTE, MD PHD FAAAAI

Financial Nothing to Disclose
Research Nothing to Disclose

GAWCHIK, SANDRA M., DO FAAAAI

Financial Schering – consultant, speaker, stock, advisory board; Astra Zeneca – consultant, speaker,
stock; Merck – consultant, speaker; GlaxoSmithKline – speaker; Sepracor – consultant,
advisory board, speaker, stock
Research Astra Zeneca, Aperon, Novartis – PI, clinical research; Skye Pharma, sanofi-aventis,
MEDA, Johnson & Johnson, Sepracor, Schering, GLAXOSMITHKLINE, Merck –
clinical research; PDZ Biopharm, Alcon, Symbio, Greer, MAP, ALK Abello, Curalogic –
clinical research

GRUCHALLA, REBECCA S., MD PHD FAAAAI

Financial Nothing to Disclose
Research ExxonMobil: A total of \$500,000 was given to Dr. Gruchalla and her research team to
conduct a community-based participatory project entitled, "Community Leadership in

Preventing Asthma - CLIP Asthma". This study is seeking to evaluate the relationship between allergens in the school and home environments and asthma symptoms in inner city children

LEDFORD, DENNIS K., MD FAAAAI

Financial	AstraZeneca, Boehringer Ingelheim, Merck, Genentech, Novartis, Schering, MedPointe, Glaxo SKF – speakers bureaus; Genentech, Schering, AstraZeneca – consultant; MedImmune, Genentech, AstraZeneca – stock
Research	Genentech, AstraZeneca, Sepracor – research support

LEUNG, DONALD Y. M., MD PHD FAAAAI

Financial	Ceragenix Corp : consultation; Arriva Pharmaceuticals: consultation; Genentech: consultation, speaker's bureau, grant; Novartis pharmaceutical corporation: consultation, speaker's bureau, grant; Efficas, Inc : consultation
Research	Novartis pharmaceutical corporation: research grant; National Institutes of Health: research grants; Genentech: research grant

LI, JAMES T., MD PHD FAAAAI

Financial	Nothing to Disclose
Research	Nothing to Disclose

RANDOLPH, CHRISTOPHER C., MD FAAAAI

Financial	Merck: Speaker's Bureau; Grant Support; Consulting; Sepracor: Speaker's Bureau; Grant Support; Consulting; AstraZeneca: Speaker's Bureau; Grant Support; Consulting; Schering: Speaker's Bureau; Grant Support; Consulting; Aventis: Speaker's Bureau; Grant Support; Consulting; Forest: Speaker's Bureau; Grant Support; Consulting; Glaxo: Speaker's Bureau; Grant Support; Consulting; Novartis: Speaker's Bureau; Grant Support; Consulting; IVAX: Speaker's Bureau; Grant Support; Consulting
Research	Astra Zeneca: Speaker's Bureau; Alcon: Speaker's Bureau and Clinical Research on products; Merck: Speaker's Bureau

Executive Staff

WHALEN, KAY – Executive Vice President

Financial	Executive Director, Inc.: Ownership Interest
Research	Nothing to Disclose

Officers

SAMPSON, HUGH A., MD FAAAAI - President

Financial	Allertein Therapeutics, LLC: Consultant on the development of novel vaccines for the treatment of allergic disorders, especially food allergy. FAARP - University of Nebraska: Scientific advisory board
Research	Phadia AB; Uppsala, Sweden: In the past year, funds were received through the University from Phadia AB for the evaluation of food allergen-specific IgE quantitative tests.

GREENBERGER, PAUL A., MD FAAAAI – President-Elect

Financial	Novartis – consultant (adjudication committee); Genentech – consultant
Research	NATIONAL HEART, LUNG AND BLOOD INSTITUTE – research support

BALLOW, MARK, MD FAAAAI – Vice President

Financial	University Pediatric Associates: Practice Plan Patient Care
Research	Nabi Biopharmaceutical: Clinical Study on IVIG NATIONAL INSTITUTES OF HEALTH: Research PBL: Clinical Study on IVIG

LEDFORD, DENNIS K., MD FAAAAI – Secretary-Treasurer

Financial	Critical Therapeutics: Speaker bureau with honoraria Genentech: Consultant and Speaker bureau honoraria. MedPointe: Speaker bureau with honoraria Merck: Speaker bureau honoraria Novartis: Consultant and speaker honoraria Sanofi Aventis: Consultant and speaker bureau with honoraria
Research	AstraZeneca: Clinical trial Genentech: Clinical trial GlaxoSKF: Clinical trial Novartis: Clinical trial Sanofi Aventis: Clinical COPD trial

PLATT'S-MILLS, THOMAS A. E., MD FAAAAI– Past Past-President

Financial	Indoor Biotechnologies: Scientific advisory board Sharper Image: Consultant/Educational Grant
Research	CENTERS FOR DISEASE CONTROL: Grants National Institutes of Health: Grants Sharper Image: Educational Grant

At-Large Members

BALLAS, ZUHAIR K., MD FAAAAI

Financial	Baxter: Consultant NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES: Member, Data and Safety Monitoring Board for Immune Tolerance Network Novartis: member of DSMB Roche: Consultant
Research	NATIONAL INSTITUTES OF HEALTH: Received grant Veterans Administration: Received Merit grant

BOCHNER, BRUCE S., MD FAAAAI

Financial Glycomimetics, Inc., Therakos: Consulting and Scientific Advisory Board
 Merck: Speaker's Bureau
 Pfizer, Genentech, Novartis, Amgen, sanofi-aventis, Ception, UCB Pharma, Domantis, Merck:

Research GLAXOSMITHKLINE, Eli Lilly, Human Genome Sciences: unfunded scientific collaborations
 NATIONAL INSTITUTES OF HEALTH, Dana Foundation: RO1 and other research grants

BROIDE, DAVID H., MB CHB FAAAAI

Financial American Thoracic Society: Honorarium for speaking at annual meeting
 Immune Tolerance Network: Asthma and Allergy Subgroup Member
 Indoor Biotechnology: Consultant
 NATIONAL INSTITUTES OF HEALTH: Grant Recipient
 Shook Hardy Bacon: expert witness for defendant regarding LABA and asthma
 Southwest Allergy Society: Honorarium

Research FAAN: Research grant
 NATIONAL INSTITUTES OF HEALTH: Research Grants

BURKS, A. WESLEY, MD FAAAAI

Financial Allertein: Minority stockholder
 Dannon Co. Probiotics: Advisory Board
 EipPen/Dey L.P.: Speaker's bureau

Research Food Allergy and Anaphylaxis Network: Grantee
 Gerber: Grantee
 Mead Johnson: Grantee
 National Institutes of Health: Grantee

COX, LINDA, MD FAAAAI

Financial Planet Technology, Greer, ,Genentech Novartis, Stallergenes, Astra-Zeneca: speaker bureau:
 Astra-Zeneca, Genentech/Novartis
 advisory boards: Greer . Schering-Plough, Allergy therapeutics, planet technology,Stallergenes

Research AAAAI: provided grants for the Immunotherapy and Allergy Diagnostics Committee
 extract stability study and extract potency comparison studies

CUNNINGHAM-RUNDLES, CHARLOTTE, MD PHD FAAAAI

Financial Nothing to Disclose

Research Nothing to Disclose

FASANO, MARY BETH, MD FAAAAI

Financial Nothing to Disclose

Research CSL Behring: Research project on IVIG and SCIG in patients with primary immunodeficiencies
 Greer Labs: Clinical research trial on sublingual immunotherapy for ragweed allergy
 LEV Pharmaceuticals: Research project on the use of a purified C1 esterase inhibitor in patients

GAWCHIK, SANDRA M., DO FAAAAI

Financial	Astra Zeneca: Consultant, speaker, stock Glaxo Smith Kline: Speaker Merck: Consultant, speaker Schering: Consultant, speaker, stock, advisory board Sepracor: Speaker, consultant, advisory board, stocks
Research	Astra Zeneca, Aponer, Novartis: Clinical research - PI PDZ Biopharm, Alcon, Symbio, Greer, MAP, ALK Abello, Curalogic: Clinical Research Skye Pharma, sanofi-aventis, MEDA, Johnson & Johnson, Sepracor, Schering, GLAXOSMITHKLINE, Merck: Clinical Research

HUSTON, DAVID P., MD FAAAAI

Financial	Nothing to Disclose
Research	Dyax Corporation: Grants/Research support Lev Pharmaceuticals: Grant/Research support National Institutes of Health: Grants/Research support

LI, JAMES T., MD PHD FAAAAI

Financial	Nothing to Disclose
Research	Nothing to Disclose

RANDOLPH, CHRISTOPHER C., MD FAAAAI

Financial	Alcon: Clinical Research and Speaker AstraZeneca: Speaker's Bureau; Grant Support; Consulting Aventis: Speaker's Bureau; Grant Support; Consulting Cornerstone Therapeutics: Speaker's Bureau Dey: Speaker's Bureau Forest: Speaker's Bureau; Grant Support; Consulting Genentech/Novartis: Speaker (Xolair Natural History Excel Study) and Clinical Research Glaxo: Speaker's Bureau; Grant Support; Consulting IVAX: Speaker's Bureau; Grant Support; Consulting Meda: Speakers Bureau Medpointe: Speaker Merck: Speaker's Bureau; Grant Support; Consulting Novartis /Genentech: Speaker and clinical research Novartis: Speaker's Bureau; Grant Support; Consulting Schering: Speaker's Bureau; Grant Support; Consulting Sepracor: Speaker's Bureau; Grant Support; Consulting UCB: Speaker's Bureau, consulting Verus: Speaker's Bureau
Research	Alcon: Clinical Research on products

WOOD, ROBERT A., MD FAAAAI

Financial	Nothing to Disclose
Research	Genentech: Research support Merck: Research support

Executive Staff

CASALE, THOMAS B., MD FAAAAI – Executive Vice President

Financial	Adelphi: Honoraria Allux Medical, Inc.: Consulting Fees Capnia, Inc.: Consulting Fees Educational Concepts in Medicine: Honoraria Genentech: Consulting fees/honoraria Gray Consulting, Inc.: Consulting Fees Merck: Honoraria Novartis Pharmaceuticals: Honoraria/Consulting Fees Wolters Kluwer Health, Inc: Royalties Zymo/Genetics: Consulting fees Zymo/Genetics: honoraria
Research	Alcon: Principal Investigator Allied Health Int'l: Principal investigator Amgen: Principal Investigator Capnia, Inc.: Principal Investigator Curalogic, Inc.: Principal investigator Dynavax, Inc.: Principal Investigator Genentech: Principal Investigator Kendle: Principal Investigator NIH: Principal/sub-Investigator Novartis Pharmaceuticals: Principal Investigator Pfizer, Inc.: Principal Investigator Schering-Plough: Principal Investigator ZLB: Sub-investigator

WHALEN, KAY – Executive Director

Financial	Executive Director, Inc.: Ownership Interest
Research	Nothing to Disclose

Officers

GREENBERGER, PAUL A., MD FAAAAI – President

Financial	Novartis – Consultant (Adjudication Committee)
Research	Nothing to Disclose

BALLOW, MARK MD FAAAAI – President-Elect

Financial	CSL Behring – Speakers Bureau; FFF Enterprises Inc. – Medical safety officer for IGIV study; Merck – Speakers Bureau
Research	Grifols Biologicals, Inc. – PI for IGIV study; Talecris Biotherapeutics – Research Grant

LEDFORD, DENNIS MD FAAAAI – Secretary-Treasurer

Financial	AstraZeneca – Consultant and Speaker Bureau with honoraria; AstraZeneca – Common Stock; Critical Therapeutics – Speaker Bureau with honoraria; Genentech - Consultant and Speaker Bureau with honoraria; Meda – Speaker Bureau; Merck – Speaker Bureau with honoraria; Novartis – Consultant and Speaker Bureau with honoraria; sanofi-aventis – Consultant and Speaker Bureau with honoraria; Sepracor – Speaker Bureau with honoraria; UCB – Speaker Bureau
Research	Genentech – Clinical Trial; Glaxo SKF – Clinical Trial; Novartis – Clinical Trial; Forrest – COPD Trial

SAMPSON, HUGH A., MD FAAAAI – Immediate Past-President

Financial	Allertein Therapeutics, LLC - Consultant on the development of novel vaccines for the treatment of allergic disorders, especially food allergy; FAARP - University of Nebraska – Scientific advisory board; Food Allergy Initiative - Consultant on issues of food allergy and food allergy research; Schering-Plough – Scientific advisory board
Research	Food Allergy Initiative - Funds received through Mount Sinai to support research projects; Phadia AB; Uppsala, Sweden - In the past year, reagents were received to support the NATIONAL INSTITUTES OF HEALTH-sponsored Inner-city Asthma Consortium and the Consortium of Food Allergy Research

At-Large Members

BALLAS, ZUHAIR K., MD FAAAAI

Financial	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES - Member, Data and Safety Monitoring Board for Immune Tolerance Network
Research	NATIONAL INSTITUTES OF HEALTH – Grant recipient; Veterans Administration – Merit grant recipient

BOCHNER, BRUCE S., MD FAAAAI

Financial	Genentech, Amgen, Pharmacyclics, GLAXOSMITHKLINE, Bristol-Myers Squibb, Bayhill Therapeutics – Consulting; Glycomimetics, Inc. - Consulting and Scientific Advisory Board; sanofi-aventis – Consulting
Research	Enobia, Sanofi-Aventis – research grants; GLAXOSMITHKLINE, Human Genome Sciences – unfunded scientific collaboration; NATIONAL INSTITUTES OF HEALTH, Dana Foundation - RO1 and other research grants

BURKS, A. WESLEY MD FAAAAI

Financial ActoGeniX – Consultant; Allertein – minority stockholder; Dannon Co. Probiotics – Advisory board; Intelliject – Advisory board; MastCell, Inc. – minority stockholder; McNeil Nutritionals – Consultant; Novartis – Consultant; Nutricia – Expert panel

Research Food Allergy and Anaphylaxis Network – Grantee; NATIONAL INSTITUTES OF HEALTH – Grantee

COX, LINDA MD FAAAAI

Financial Genentech/Novartis – Consultant, Speaker bureau; ISTA – Medical Advisory Board; sanofi-aventis – Speaker bureau; Schering-Plough – Medical Advisory Board; Stallergenes – Consultant

Research Nothing to Disclose

CUNNINGHAM-RUNDLES, CHARLOTTE MD PhD FAAAAI

Financial Talecris – Medical Advisory Board

Research Baxter Healthcare – Research grant

DYKEWICZ, MARK S. MD FAAAAI

Financial Alcon, Boehringer-Ingelheim, Dyax, ISTA, – Advisor, Honorarium; Merck – Speakers Bureau, Honorarium; Genentech/Novartis – Advisor, Speakers Bureau, Honorarium

Research Lincoln Diagnostics, Genentech/Novartis, Schering, ViroPharma/Lev – research contracts with Saint Louis University

FASANO, MARY BETH MD FAAAAI

Financial Nothing to Disclose

Research Jerini US, Inc - PI Clinical Trial - A Phase III Randomized Double-blind, Placebo-controlled multicenter study of Icatibant for subcutaneous injection in patients with acute attacks of hereditary angioedema (HAE); Baxter - PI Clinical Trial - Efficacy, tolerability and pharmacokinetic comparison of immune globulin intravenous (human), 10% (Gammagard liquid/Kiovig) administered intravenously or subcutaneously following administration of recombinant human hyaluronidase (rHuPH20) in subjects with primary immunodeficiency diseases

HUSTON, DAVID P. MD FAAAAI

Financial Nothing to Disclose

Research NATIONAL INSTITUTES OF HEALTH – Grants/Research support

IRANI, ANNE-MARIE A. MD FAAAAI

Financial Merck – Speaker Bureau ; Phadia – Virginia Commonwealth University receives royalties that are shared with Dr. Lawrence Schwartz (spouse)

Research Astra-Zeneca, Aventis, Ception Inc., GlaxoSmithKline, Genentech/Novartis, Schering, Meritage – Research grants

RANDOLPH, CHRISTOPHER C. MD FAAAAI

Financial Accredo, Alcon, AstraZeneca, Baxter, Cornerstone Therapeutics, Dey, Genentech/Novartis (Xolair Natural History Excel Study), GlaxoSmithKline, Meda, Merck, Pfizer, sanofi-aventis, Schering, Sciele Pharma Inc., Sepracor, TEVA, Verus, Wallace – Speaker Bureaus

Research Alcon – research grant

WINDOM, HUGH H. MD FAAAAI

Financial Nothing to Disclose

Research Genentech, Schering-Plough, Novartis, Amgen – multi-center clinical research trials

WOOD, ROBERT A. MD FAAAAI

Financial Nothing to Disclose

Research Genentech – Research support

Executive Staff**CASALE, THOMAS B., MD FAAAAI – Executive Vice President**

Financial Educational Concepts in Medicine: speaker honoraria

MediCine Inc.: honoraria for Respiratory Digest

MedImmune: Consulting fees

MedPoint Communications: speaker honoraria

Wolters Kluwer Health: royalties

Research Alcon: Principal Investigator

Allergy Therapeutics: Principal Investigator

Capnia, Inc.: Principal Investigator

Greer: Principal Investigator

Merck: Principal Investigator

NIH: Principal/Sub Investigator

Novartis: Principal Investigator

Pfizer: Principal Investigator

Schering-Plough: Principal Investigator

Stallergenes: Principal Investigator

ZLB: Sub-investigator

Medimmune: Principal Investigator

Health Future Foundation: Principal Investigator

Genentech: Sub-investigator

Boehringer Ingelheim: Principal Investigator

WHALEN, KAY – Executive Director

Financial Executive Director, Inc.: Ownership Interest

Research Nothing to Disclose